Biosimilars Market Size By Product (Recombinant Non-Glycosylated Proteins {Human Growth Hormone, Granulocyte Colony-Stimulating Factor, Insulin, Interferon}, Recombinant Glycosylated Proteins {Erythropoietin, Monoclonal Antibodies, Follitropin, Low Molecular Weight Heparin}), By Application (Hematology {Neutropenia, Anemia}, Oncology {Lung Cancer, Brain Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Leukemia or Blood Cancer}, Autoimmune Disease {Arthritis, Inflammatory Bowel Disease, Psoriasis}, Growth Hormone Deficiency, Diabetes), By Manufacturer (Contract Research and Manufacturing Services, In-house), By Technology (Recombinant DNA Technology, Monoclonal Antibodies Technology) Industry Analysis Report, Regional Outlook, Application Potential, COVID-19 Impact Analysis, Competitive Market Share & Forecast, 2022 – 2030

Report Content

Chapter 1   Methodology

1.1    Market definitions

1.2    Base estimates & working

1.3    Forecast parameters

1.4    Data validation

1.5    Data sources

1.5.1    Secondary

1.5.1.1   Paid sources

1.5.1.2   Unpaid sources

1.5.2    Primary

Chapter 2   Executive Summary

2.1    Biosimilars industry 360⁰ synopsis, 2017-2030 (USD Million)

2.1.1    Business trends

2.1.2    Product trends

2.1.3    Application trends

2.1.4    Manufacturer trends

2.1.5    Technology trends

2.1.6    Regional trends

Chapter 3   Biosimilars Industry Insights

3.1    Industry segmentation

3.2    Industry landscape, 2017-2030 (USD Million)

3.3    Industry impact factors

3.3.1    Growth drivers

3.3.1.1   Strong product pipeline

3.3.1.2   Rise in prevalence of chronic diseases across the globe

3.3.1.3   Expiry of blockbuster biologics

3.3.1.4   Cost-effectiveness of biosimilars

3.3.1.5   Recent biosimilar product approvals in major countries

3.3.2    Industry pitfalls & challenges

3.3.2.1   Availability of alternative medications

3.3.2.2   Regulatory Uncertainty

3.3.2.3   High developmental costs

3.3.2.4   Complex manufacturing process

3.4    Growth potential analysis

3.4.1    By product

3.4.2    By application

3.4.3    By manufacturer

3.4.4    By technology

3.5    COVID-19 impact analysis

3.6    PORTER’s Analysis

3.7    Regulatory landscape

3.7.1    U.S.

3.7.2    Canada

3.7.3    Europe

3.7.4    India

3.7.5    Japan

3.7.6    South Korea

3.7.7    Australia

3.7.8    Singapore

3.8    Reimbursement landscape

3.8.1    U.S.

3.8.2    Europe

3.8.3    Canada

3.8.4    Australia

3.8.5    New Zealand

3.9    Market analysis

3.9.1    Strength

3.9.2    Weakness

3.9.3    Opportunity

3.9.4    Threat

3.10    U.S. biosimilars insurance coverage, 2021

3.11    Biosimilar litigation landscape

3.12    Biosimilar product pipeline analysis

3.12.1    Amgen

3.12.2    Biocon

3.12.3    Sandoz

3.12.4    Celltrion

3.12.5    Coherus BioSciences

3.12.6    Fresenius Kabi

3.12.7    Pfizer

3.12.8    Lupin

3.12.9    Samsung Bioepis

3.12.10    Teva Pharmaceuticals

3.13    Biosimilars approval scenario, 2017-2022

3.13.1    U.S.

3.13.2    Canada

3.13.3    Europe

3.13.4    India

3.13.5    South Korea

3.13.6    Australia

3.13.7    New Zealand

3.13.8    Singapore

3.13.9    Malaysia

3.14    Biologics patent expiry scenario

3.15    Biosimilars industry evolution

3.16    Biosimilars factor analysis

3.16.1    Access

3.16.2    Regulations

3.16.3    Payer assessment and access

3.16.4    Physician acceptance

3.16.5    Patient acceptance

3.16.6    Number of biosimilar approvals

3.17    Biosimilars landscape - country analysis

3.17.1    U.S.

3.17.2    Europe

3.17.3    China

3.17.4    Japan

3.17.5    India

3.17.6    South Korea

3.18    Key market success factors

3.19    International policies on use of biosimilar drugs

3.19.1    Interchangeability, Switching and Substitution

3.19.2    Supply Side Policies

3.19.3    Prescribing Incentives

3.20    Competitive landscape, 2021

3.20.1    Competitive matrix analysis, 2021

3.21    PESTEL analysis

Chapter 4   Biosimilars Market, By Product

4.1    Key segment trends

4.2    Recombinant Non-Glycosylated Proteins

4.2.1    Market size, by region, 2017-2030 (USD Million)

4.2.2    Human Growth Hormone

4.2.2.1   Market size, by region, 2017-2030 (USD Million)

4.2.3    Granulocyte Colony-Stimulating Factor (Filgrastim)

4.2.3.1   Market size, by region, 2017-2030 (USD Million)

4.2.4    Insulin

4.2.4.1   Market size, by region, 2017-2030 (USD Million)

4.2.5    Interferon

4.2.5.1   Market size, by region, 2017-2030 (USD Million)

4.2.5.2   Alfa

4.2.5.2.1    Market size, by region, 2017-2030 (USD Million)

4.2.5.3   Beta

4.2.5.3.1    Market size, by region, 2017-2030 (USD Million)

4.3    Recombinant Glycosylated Proteins

4.3.1    Market size, by region, 2017-2030 (USD Million)

4.3.2    Erythropoietin

4.3.2.1   Market size, by region, 2017-2030 (USD Million)

4.3.2.2   Alfa

4.3.2.2.1    Market size, by region, 2017-2030 (USD Million)

4.3.2.3   Zeta

4.3.2.3.1    Market size, by region, 2017-2030 (USD Million)

4.3.3    Monoclonal Antibodies

4.3.3.1   Market size, by region, 2017-2030 (USD Million)

4.3.3.2   Infliximab

4.3.3.2.1    Market size, by region, 2017-2030 (USD Million)

4.3.3.3   Rituximab

4.3.3.3.1    Market size, by region, 2017-2030 (USD Million)

4.3.3.4   Adalimumab

4.3.3.4.1    Market size, by region, 2017-2030 (USD Million)

4.3.3.5   Trastuzumab

4.3.3.5.1    Market size, by region, 2017-2030 (USD Million)

4.3.3.6   Bevacizumab

4.3.3.6.1    Market size, by region, 2017-2030 (USD Million)

4.3.3.7   Etanercept

4.3.3.7.1    Market size, by region, 2017-2030 (USD Million)

4.3.4    Follitropin

4.3.4.1   Market size, by region, 2017-2030 (USD Million)

4.3.4.2   Alfa

4.3.4.2.1    Market size, by region, 2017-2030 (USD Million)

4.3.4.3   Beta

4.3.4.3.1    Market size, by region, 2017-2030 (USD Million)

4.3.5    Low Molecular Weight Heparin (LMWHs)

4.3.5.1   Market size, by region, 2017-2030 (USD Million)

Chapter 5   Biosimilars Market, By Application

5.1    Key segment trends

5.2    Hematology

5.2.1    Market size, by region, 2017-2030 (USD Million)

5.2.2    Neutropenia

5.2.2.1   Market size, by region, 2017-2030 (USD Million)

5.2.3    Anemia

5.2.3.1   Market size, by region, 2017-2030 (USD Million)

5.2.4    Others

5.2.4.1   Market size, by region, 2017-2030 (USD Million)

5.3    Oncology

5.3.1    Market size, by region, 2017-2030 (USD Million)

5.3.2    Lung Cancer

5.3.2.1   Market size, by region, 2017-2030 (USD Million)

5.3.3    Brain Cancer

5.3.3.1   Market size, by region, 2017-2030 (USD Million)

5.3.4    Breast Cancer

5.3.4.1   Market size, by region, 2017-2030 (USD Million)

5.3.5    Cervical Cancer

5.3.5.1   Market size, by region, 2017-2030 (USD Million)

5.3.6    Colorectal Cancer

5.3.6.1   Market size, by region, 2017-2030 (USD Million)

5.3.7    Leukemia

5.3.7.1   Market size, by region, 2017-2030 (USD Million)

5.3.7.2   Non-Hodgkin Lymphoma (NHL)

5.3.7.2.1    Market size, by region, 2017-2030 (USD Million)

5.3.7.3   Chronic Lymphocytic Leukemia (CLL)

5.3.7.3.1    Market size, by region, 2017-2030 (USD Million)

5.3.7.4   Others

5.3.7.4.1    Market size, by region, 2017-2030 (USD Million)

5.3.8    Others

5.3.8.1   Market size, by region, 2017-2030 (USD Million)

5.4    Autoimmune Disease

5.4.1    Market size, by region, 2017-2030 (USD Million)

5.4.2    Arthritis

5.4.2.1   Market size, by region, 2017-2030 (USD Million)

5.4.2.2   Rheumatoid Arthritis

5.4.2.2.1    Market size, by region, 2017-2030 (USD Million)

5.4.2.3   Psoriatic Arthritis

5.4.2.3.1    Market size, by region, 2017-2030 (USD Million)

5.4.2.4   Juvenile Arthritis

5.4.2.4.1    Market size, by region, 2017-2030 (USD Million)

5.4.2.5   Ankylosing Spondylitis

5.4.2.5.1    Market size, by region, 2017-2030 (USD Million)

5.4.2.6   Others

5.4.2.6.1    Market size, by region, 2017-2030 (USD Million)

5.4.3    Inflammatory Bowel Disease (IBD)

5.4.3.1   Market size, by region, 2017-2030 (USD Million)

5.4.3.2   Ulcerative Colitis

5.4.3.2.1    Market size, by region, 2017-2030 (USD Million)

5.4.3.3   Crohn's Disease

5.4.3.3.1    Market size, by region, 2017-2030 (USD Million)

5.4.3.4   Others

5.4.3.4.1    Market size, by region, 2017-2030 (USD Million)

5.4.4    Psoriasis

5.4.4.1   Market size, by region, 2017-2030 (USD Million)

5.4.5    Others

5.4.5.1   Market size, by region, 2017-2030 (USD Million)

5.5    Growth Hormone Deficiency

5.5.1    Market size, by region, 2017-2030 (USD Million)

5.6    Diabetes

5.6.1    Market size, by region, 2017-2030 (USD Million)

5.7    Others

5.7.1    Market size, by region, 2017-2030 (USD Million)

Chapter 6   Biosimilars Market, By Manufacturer

6.1    Key segment trends

6.2    Contract Research and Manufacturing Services

6.2.1    Market size, by region, 2017-2030 (USD Million)

6.3    In-house

6.3.1    Market size, by region, 2017-2030 (USD Million)

Chapter 7   Biosimilars Market, By Technology

7.1    Key segment trends

7.2    Recombinant DNA Technology (rDNA technology)

7.2.1    Market size, by region, 2017-2030 (USD Million)

7.3    Monoclonal Antibodies (MAb) Technology

7.3.1    Market size, by region, 2017-2030 (USD Million)

Chapter 8   Biosimilars Market, By Region

8.1    Key regional trends

8.2    North America

8.2.1    Market size, by country, 2017-2030 (USD Million)

8.2.2    Market size, by product, 2017-2030 (USD Million)

8.2.2.1   Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)

8.2.2.2   Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)

8.2.2.2.1    Market size, by monoclonal antibodies, 2017-2030 (USD Million)

8.2.3    Market size, by application, 2017-2030 (USD Million)

8.2.3.1   Market size, by hematology, 2017-2030 (USD Million)

8.2.3.2   Market size, by oncology, 2017-2030 (USD Million)

8.2.3.2.1    Market size, by leukemia, 2017-2030 (USD Million)

8.2.3.3   Market size, by autoimmune disease, 2017-2030 (USD Million)

8.2.3.3.1    Market size, by arthritis, 2017-2030 (USD Million)

8.2.3.3.2    Market size, by inflammatory bowel disease, 2017-2030 (USD Million)

8.2.4    Market size, by manufacturer, 2017-2030 (USD Million)

8.2.5    Market size, by technology, 2017-2030 (USD Million)

8.2.6    U.S.

8.2.6.1   Market size, by product, 2017-2030 (USD Million)

8.2.6.1.1    Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)

8.2.6.1.2    Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)

8.2.6.1.2.1    Market size, by monoclonal antibodies, 2017-2030 (USD Million)

8.2.6.2   Market size, by application, 2017-2030 (USD Million)

8.2.6.2.1    Market size, by hematology, 2017-2030 (USD Million)

8.2.6.2.2    Market size, by oncology, 2017-2030 (USD Million)

8.2.6.2.2.1    Market size, by leukemia, 2017-2030 (USD Million)

8.2.6.2.3    Market size, by autoimmune disease, 2017-2030 (USD Million)

8.2.6.2.3.1    Market size, by arthritis, 2017-2030 (USD Million)

8.2.6.2.3.2    Market size, by inflammatory bowel disease, 2017-2030 (USD Million)

8.2.6.3   Market size, by manufacturer, 2017-2030 (USD Million)

8.2.6.4   Market size, by technology, 2017-2030 (USD Million)

8.2.7    Canada

8.2.7.1   Market size, by product, 2017-2030 (USD Million)

8.2.7.1.1    Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)

8.2.7.1.2    Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)

8.2.7.1.2.1    Market size, by monoclonal antibodies, 2017-2030 (USD Million)

8.2.7.2   Market size, by application, 2017-2030 (USD Million)

8.2.7.2.1    Market size, by hematology, 2017-2030 (USD Million)

8.2.7.2.2    Market size, by autoimmune disease, 2017-2030 (USD Million)

8.2.7.2.2.1    Market size, by arthritis, 2017-2030 (USD Million)

8.2.7.2.2.2    Market size, by inflammatory bowel disease, 2017-2030 (USD Million)

8.2.7.3   Market size, by manufacturer, 2017-2030 (USD Million)

8.2.7.4   Market size, by technology, 2017-2030 (USD Million)

8.3    Europe

8.3.1    Market size, by country, 2017-2030 (USD Million)

8.3.2    Market size, by product, 2017-2030 (USD Million)

8.3.2.1   Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)

8.3.2.1.1    Market size, by interferon, 2017-2030 (USD Million)

8.3.2.2   Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)

8.3.2.2.1    Market size, by erythropoietin, 2017-2030 (USD Million)

8.3.2.2.2    Market size, by monoclonal antibodies, 2017-2030 (USD Million)

8.3.2.2.3    Market size, by follitropin, 2017-2030 (USD Million)

8.3.3    Market size, by application, 2017-2030 (USD Million)

8.3.3.1   Market size, by hematology, 2017-2030 (USD Million)

8.3.3.2   Market size, by oncology, 2017-2030 (USD Million)

8.3.3.2.1    Market size, by leukemia, 2017-2030 (USD Million)

8.3.3.3   Market size, by autoimmune disease, 2017-2030 (USD Million)

8.3.3.3.1    Market size, by arthritis, 2017-2030 (USD Million)

8.3.3.3.2    Market size, by inflammatory bowel disease, 2017-2030 (USD Million)

8.3.4    Market size, by manufacturer, 2017-2030 (USD Million)

8.3.5    Market size, by technology, 2017-2030 (USD Million)

8.3.6    Germany

8.3.6.1   Market size, by product, 2017-2030 (USD Million)

8.3.6.1.1    Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)

8.3.6.1.1.1    Market size, by interferon, 2017-2030 (USD Million)

8.3.6.1.2    Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)

8.3.6.1.2.1    Market size, by erythropoietin, 2017-2030 (USD Million)

8.3.6.1.2.2    Market size, by monoclonal antibodies, 2017-2030 (USD Million)

8.3.6.1.2.3    Market size, by follitropin, 2017-2030 (USD Million)

8.3.6.2   Market size, by application, 2017-2030 (USD Million)

8.3.6.2.1    Market size, by hematology, 2017-2030 (USD Million)

8.3.6.2.2    Market size, by oncology, 2017-2030 (USD Million)

8.3.6.2.2.1    Market size, by leukemia, 2017-2030 (USD Million)

8.3.6.2.3    Market size, by autoimmune disease, 2017-2030 (USD Million)

8.3.6.2.3.1    Market size, by arthritis, 2017-2030 (USD Million)

8.3.6.2.3.2    Market size, by inflammatory bowel disease, 2017-2030 (USD Million)

8.3.6.3   Market size, by manufacturer, 2017-2030 (USD Million)

8.3.6.4   Market size, by technology, 2017-2030 (USD Million)

8.3.7    UK

8.3.7.1   Market size, by product, 2017-2030 (USD Million)

8.3.7.1.1    Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)

8.3.7.1.1.1    Market size, by interferon, 2017-2030 (USD Million)

8.3.7.1.2    Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)

8.3.7.1.2.1    Market size, by erythropoietin, 2017-2030 (USD Million)

8.3.7.1.2.2    Market size, by monoclonal antibodies, 2017-2030 (USD Million)

8.3.7.1.2.3    Market size, by follitropin, 2017-2030 (USD Million)

8.3.7.2   Market size, by application, 2017-2030 (USD Million)

8.3.7.2.1    Market size, by hematology, 2017-2030 (USD Million)

8.3.7.2.2    Market size, by oncology, 2017-2030 (USD Million)

8.3.7.2.2.1    Market size, by leukemia, 2017-2030 (USD Million)

8.3.7.2.3    Market size, by autoimmune disease, 2017-2030 (USD Million)

8.3.7.2.3.1    Market size, by arthritis, 2017-2030 (USD Million)

8.3.7.2.3.2    Market size, by inflammatory bowel disease, 2017-2030 (USD Million)

8.3.7.3   Market size, by manufacturer, 2017-2030 (USD Million)

8.3.7.4   Market size, by technology, 2017-2030 (USD Million)

8.3.8    France

8.3.8.1   Market size, by product, 2017-2030 (USD Million)

8.3.8.1.1    Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)

8.3.8.1.1.1    Market size, by interferon, 2017-2030 (USD Million)

8.3.8.1.2    Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)

8.3.8.1.2.1    Market size, by erythropoietin, 2017-2030 (USD Million)

8.3.8.1.2.2    Market size, by monoclonal antibodies, 2017-2030 (USD Million)

8.3.8.1.2.3    Market size, by follitropin, 2017-2030 (USD Million)

8.3.8.2   Market size, by application, 2017-2030 (USD Million)

8.3.8.2.1    Market size, by hematology, 2017-2030 (USD Million)

8.3.8.2.2    Market size, by oncology, 2017-2030 (USD Million)

8.3.8.2.2.1    Market size, by leukemia, 2017-2030 (USD Million)

8.3.8.2.3    Market size, by autoimmune disease, 2017-2030 (USD Million)

8.3.8.2.3.1    Market size, by arthritis, 2017-2030 (USD Million)

8.3.8.2.3.2    Market size, by inflammatory bowel disease, 2017-2030 (USD Million)

8.3.8.3   Market size, by manufacturer, 2017-2030 (USD Million)

8.3.8.4   Market size, by technology, 2017-2030 (USD Million)

8.3.9    Spain

8.3.9.1   Market size, by product, 2017-2030 (USD Million)

8.3.9.1.1    Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)

8.3.9.1.1.1    Market size, by interferon, 2017-2030 (USD Million)

8.3.9.1.2    Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)

8.3.9.1.2.1    Market size, by erythropoietin, 2017-2030 (USD Million)

8.3.9.1.2.2    Market size, by monoclonal antibodies, 2017-2030 (USD Million)

8.3.9.1.2.3    Market size, by follitropin, 2017-2030 (USD Million)

8.3.9.2   Market size, by application, 2017-2030 (USD Million)

8.3.9.2.1    Market size, by hematology, 2017-2030 (USD Million)

8.3.9.2.2    Market size, by oncology, 2017-2030 (USD Million)

8.3.9.2.2.1    Market size, by leukemia, 2017-2030 (USD Million)

8.3.9.2.3    Market size, by autoimmune disease, 2017-2030 (USD Million)

8.3.9.2.3.1    Market size, by arthritis, 2017-2030 (USD Million)

8.3.9.2.3.2    Market size, by inflammatory bowel disease, 2017-2030 (USD Million)

8.3.9.3   Market size, by manufacturer, 2017-2030 (USD Million)

8.3.9.4   Market size, by technology, 2017-2030 (USD Million)

8.3.10    Italy

8.3.10.1    Market size, by product, 2017-2030 (USD Million)

8.3.10.1.1    Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)

8.3.10.1.1.1    Market size, by interferon, 2017-2030 (USD Million)

8.3.10.1.2    Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)

8.3.10.1.2.1    Market size, by erythropoietin, 2017-2030 (USD Million)

8.3.10.1.2.2    Market size, by monoclonal antibodies, 2017-2030 (USD Million)

8.3.10.1.2.3    Market size, by follitropin, 2017-2030 (USD Million)

8.3.10.2    Market size, by application, 2017-2030 (USD Million)

8.3.10.2.1    Market size, by hematology, 2017-2030 (USD Million)

8.3.10.2.2    Market size, by oncology, 2017-2030 (USD Million)

8.3.10.2.2.1    Market size, by leukemia, 2017-2030 (USD Million)

8.3.10.2.3    Market size, by autoimmune disease, 2017-2030 (USD Million)

8.3.10.2.3.1    Market size, by arthritis, 2017-2030 (USD Million)

8.3.10.2.3.2    Market size, by inflammatory bowel disease, 2017-2030 (USD Million)

8.3.10.3    Market size, by manufacturer, 2017-2030 (USD Million)

8.3.10.4    Market size, by technology, 2017-2030 (USD Million)

8.3.11    Turkey

8.3.11.1    Market size, by product, 2017-2030 (USD Million)

8.3.11.1.1    Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)

8.3.11.1.1.1    Market size, by interferon, 2017-2030 (USD Million)

8.3.11.1.2    Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)

8.3.11.1.2.1    Market size, by erythropoietin, 2017-2030 (USD Million)

8.3.11.1.2.2    Market size, by monoclonal antibodies, 2017-2030 (USD Million)

8.3.11.1.2.3    Market size, by follitropin, 2017-2030 (USD Million)

8.3.11.2    Market size, by application, 2017-2030 (USD Million)

8.3.11.2.1    Market size, by hematology, 2017-2030 (USD Million)

8.3.11.2.2    Market size, by oncology, 2017-2030 (USD Million)

8.3.11.2.2.1    Market size, by leukemia, 2017-2030 (USD Million)

8.3.11.2.3    Market size, by autoimmune disease, 2017-2030 (USD Million)

8.3.11.2.3.1    Market size, by arthritis, 2017-2030 (USD Million)

8.3.11.2.3.2    Market size, by inflammatory bowel disease, 2017-2030 (USD Million)

8.3.11.3    Market size, by manufacturer, 2017-2030 (USD Million)

8.3.11.4    Market size, by technology, 2017-2030 (USD Million)

8.3.12    Austria

8.3.12.1    Market size, by product, 2017-2030 (USD Million)

8.3.12.1.1    Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)

8.3.12.1.1.1    Market size, by interferon, 2017-2030 (USD Million)

8.3.12.1.2    Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)

8.3.12.1.2.1    Market size, by erythropoietin, 2017-2030 (USD Million)

8.3.12.1.2.2    Market size, by monoclonal antibodies, 2017-2030 (USD Million)

8.3.12.1.2.3    Market size, by follitropin, 2017-2030 (USD Million)

8.3.12.2    Market size, by application, 2017-2030 (USD Million)

8.3.12.2.1    Market size, by hematology, 2017-2030 (USD Million)

8.3.12.2.2    Market size, by oncology, 2017-2030 (USD Million)

8.3.12.2.2.1    Market size, by leukemia, 2017-2030 (USD Million)

8.3.12.2.3    Market size, by autoimmune disease, 2017-2030 (USD Million)

8.3.12.2.3.1    Market size, by arthritis, 2017-2030 (USD Million)

8.3.12.2.3.2    Market size, by inflammatory bowel disease, 2017-2030 (USD Million)

8.3.12.3    Market size, by manufacturer, 2017-2030 (USD Million)

8.3.12.4    Market size, by technology, 2017-2030 (USD Million)

8.3.13    Belgium

8.3.13.1    Market size, by product, 2017-2030 (USD Million)

8.3.13.1.1    Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)

8.3.13.1.1.1    Market size, by interferon, 2017-2030 (USD Million)

8.3.13.1.2    Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)

8.3.13.1.2.1    Market size, by erythropoietin, 2017-2030 (USD Million)

8.3.13.1.2.2    Market size, by monoclonal antibodies, 2017-2030 (USD Million)

8.3.13.1.2.3    Market size, by follitropin, 2017-2030 (USD Million)

8.3.13.2    Market size, by application, 2017-2030 (USD Million)

8.3.13.2.1    Market size, by hematology, 2017-2030 (USD Million)

8.3.13.2.2    Market size, by oncology, 2017-2030 (USD Million)

8.3.13.2.2.1    Market size, by leukemia, 2017-2030 (USD Million)

8.3.13.2.3    Market size, by autoimmune disease, 2017-2030 (USD Million)

8.3.13.2.3.1    Market size, by arthritis, 2017-2030 (USD Million)

8.3.13.2.3.2    Market size, by inflammatory bowel disease, 2017-2030 (USD Million)

8.3.13.3    Market size, by manufacturer, 2017-2030 (USD Million)

8.3.13.4    Market size, by technology, 2017-2030 (USD Million)

8.3.14    Bulgaria

8.3.14.1    Market size, by product, 2017-2030 (USD Million)

8.3.14.1.1    Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)

8.3.14.1.1.1    Market size, by interferon, 2017-2030 (USD Million)

8.3.14.1.2    Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)

8.3.14.1.2.1    Market size, by erythropoietin, 2017-2030 (USD Million)

8.3.14.1.2.2    Market size, by monoclonal antibodies, 2017-2030 (USD Million)

8.3.14.1.2.3    Market size, by follitropin, 2017-2030 (USD Million)

8.3.14.2    Market size, by application, 2017-2030 (USD Million)

8.3.14.2.1    Market size, by hematology, 2017-2030 (USD Million)

8.3.14.2.2    Market size, by oncology, 2017-2030 (USD Million)

8.3.14.2.2.1    Market size, by leukemia, 2017-2030 (USD Million)

8.3.14.2.3    Market size, by autoimmune disease, 2017-2030 (USD Million)

8.3.14.2.3.1    Market size, by arthritis, 2017-2030 (USD Million)

8.3.14.2.3.2    Market size, by inflammatory bowel disease, 2017-2030 (USD Million)

8.3.14.3    Market size, by manufacturer, 2017-2030 (USD Million)

8.3.14.4    Market size, by technology, 2017-2030 (USD Million)

8.3.15    Czech Republic

8.3.15.1    Market size, by product, 2017-2030 (USD Million)

8.3.15.1.1    Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)

8.3.15.1.1.1    Market size, by interferon, 2017-2030 (USD Million)

8.3.15.1.2    Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)

8.3.15.1.2.1    Market size, by erythropoietin, 2017-2030 (USD Million)

8.3.15.1.2.2    Market size, by monoclonal antibodies, 2017-2030 (USD Million)

8.3.15.1.2.3    Market size, by follitropin, 2017-2030 (USD Million)

8.3.15.2    Market size, by application, 2017-2030 (USD Million)

8.3.15.2.1    Market size, by hematology, 2017-2030 (USD Million)

8.3.15.2.2    Market size, by oncology, 2017-2030 (USD Million)

8.3.15.2.2.1    Market size, by leukemia, 2017-2030 (USD Million)

8.3.15.2.3    Market size, by autoimmune disease, 2017-2030 (USD Million)

8.3.15.2.3.1    Market size, by arthritis, 2017-2030 (USD Million)

8.3.15.2.3.2    Market size, by inflammatory bowel disease, 2017-2030 (USD Million)

8.3.15.3    Market size, by manufacturer, 2017-2030 (USD Million)

8.3.15.4    Market size, by technology, 2017-2030 (USD Million)

8.3.16    Denmark

8.3.16.1    Market size, by product, 2017-2030 (USD Million)

8.3.16.1.1    Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)

8.3.16.1.1.1    Market size, by interferon, 2017-2030 (USD Million)

8.3.16.1.2    Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)

8.3.16.1.2.1    Market size, by erythropoietin, 2017-2030 (USD Million)

8.3.16.1.2.2    Market size, by monoclonal antibodies, 2017-2030 (USD Million)

8.3.16.1.2.3    Market size, by follitropin, 2017-2030 (USD Million)

8.3.16.2    Market size, by application, 2017-2030 (USD Million)

8.3.16.2.1    Market size, by hematology, 2017-2030 (USD Million)

8.3.16.2.2    Market size, by oncology, 2017-2030 (USD Million)

8.3.16.2.2.1    Market size, by leukemia, 2017-2030 (USD Million)

8.3.16.2.3    Market size, by autoimmune disease, 2017-2030 (USD Million)

8.3.16.2.3.1    Market size, by arthritis, 2017-2030 (USD Million)

8.3.16.2.3.2    Market size, by inflammatory bowel disease, 2017-2030 (USD Million)

8.3.16.3    Market size, by manufacturer, 2017-2030 (USD Million)

8.3.16.4    Market size, by technology, 2017-2030 (USD Million)

8.3.17    Finland

8.3.17.1    Market size, by product, 2017-2030 (USD Million)

8.3.17.1.1    Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)

8.3.17.1.1.1    Market size, by interferon, 2017-2030 (USD Million)

8.3.17.1.2    Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)

8.3.17.1.2.1    Market size, by erythropoietin, 2017-2030 (USD Million)

8.3.17.1.2.2    Market size, by monoclonal antibodies, 2017-2030 (USD Million)

8.3.17.1.2.3    Market size, by follitropin, 2017-2030 (USD Million)

8.3.17.2    Market size, by application, 2017-2030 (USD Million)

8.3.17.2.1    Market size, by hematology, 2017-2030 (USD Million)

8.3.17.2.2    Market size, by oncology, 2017-2030 (USD Million)

8.3.17.2.2.1    Market size, by leukemia, 2017-2030 (USD Million)

8.3.17.2.3    Market size, by autoimmune disease, 2017-2030 (USD Million)

8.3.17.2.3.1    Market size, by arthritis, 2017-2030 (USD Million)

8.3.17.2.3.2    Market size, by inflammatory bowel disease, 2017-2030 (USD Million)

8.3.17.3    Market size, by manufacturer, 2017-2030 (USD Million)

8.3.17.4    Market size, by technology, 2017-2030 (USD Million)

8.3.18    Greece

8.3.18.1    Market size, by product, 2017-2030 (USD Million)

8.3.18.1.1    Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)

8.3.18.1.1.1    Market size, by interferon, 2017-2030 (USD Million)

8.3.18.1.2    Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)

8.3.18.1.2.1    Market size, by erythropoietin, 2017-2030 (USD Million)

8.3.18.1.2.2    Market size, by monoclonal antibodies, 2017-2030 (USD Million)

8.3.18.1.2.3    Market size, by follitropin, 2017-2030 (USD Million)

8.3.18.2    Market size, by application, 2017-2030 (USD Million)

8.3.18.2.1    Market size, by hematology, 2017-2030 (USD Million)

8.3.18.2.2    Market size, by oncology, 2017-2030 (USD Million)

8.3.18.2.2.1    Market size, by leukemia, 2017-2030 (USD Million)

8.3.18.2.3    Market size, by autoimmune disease, 2017-2030 (USD Million)

8.3.18.2.3.1    Market size, by arthritis, 2017-2030 (USD Million)

8.3.18.2.3.2    Market size, by inflammatory bowel disease, 2017-2030 (USD Million)

8.3.18.3    Market size, by manufacturer, 2017-2030 (USD Million)

8.3.18.4    Market size, by technology, 2017-2030 (USD Million)

8.3.19    Hungary

8.3.19.1    Market size, by product, 2017-2030 (USD Million)

8.3.19.1.1    Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)

8.3.19.1.1.1    Market size, by interferon, 2017-2030 (USD Million)

8.3.19.1.2    Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)

8.3.19.1.2.1    Market size, by erythropoietin, 2017-2030 (USD Million)

8.3.19.1.2.2    Market size, by monoclonal antibodies, 2017-2030 (USD Million)

8.3.19.1.2.3    Market size, by follitropin, 2017-2030 (USD Million)

8.3.19.2    Market size, by application, 2017-2030 (USD Million)

8.3.19.2.1    Market size, by hematology, 2017-2030 (USD Million)

8.3.19.2.2    Market size, by oncology, 2017-2030 (USD Million)

8.3.19.2.2.1    Market size, by leukemia, 2017-2030 (USD Million)

8.3.19.2.3    Market size, by autoimmune disease, 2017-2030 (USD Million)

8.3.19.2.3.1    Market size, by arthritis, 2017-2030 (USD Million)

8.3.19.2.3.2    Market size, by inflammatory bowel disease, 2017-2030 (USD Million)

8.3.19.3    Market size, by manufacturer, 2017-2030 (USD Million)

8.3.19.4    Market size, by technology, 2017-2030 (USD Million)

8.3.20    Ireland

8.3.20.1    Market size, by product, 2017-2030 (USD Million)

8.3.20.1.1    Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)

8.3.20.1.1.1    Market size, by interferon, 2017-2030 (USD Million)

8.3.20.1.2    Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)

8.3.20.1.2.1    Market size, by erythropoietin, 2017-2030 (USD Million)

8.3.20.1.2.2    Market size, by monoclonal antibodies, 2017-2030 (USD Million)

8.3.20.1.2.3    Market size, by follitropin, 2017-2030 (USD Million)

8.3.20.2    Market size, by application, 2017-2030 (USD Million)

8.3.20.2.1    Market size, by hematology, 2017-2030 (USD Million)

8.3.20.2.2    Market size, by oncology, 2017-2030 (USD Million)

8.3.20.2.2.1    Market size, by leukemia, 2017-2030 (USD Million)

8.3.20.2.3    Market size, by autoimmune disease, 2017-2030 (USD Million)

8.3.20.2.3.1    Market size, by arthritis, 2017-2030 (USD Million)

8.3.20.2.3.2    Market size, by inflammatory bowel disease, 2017-2030 (USD Million)

8.3.20.3    Market size, by manufacturer, 2017-2030 (USD Million)

8.3.20.4    Market size, by technology, 2017-2030 (USD Million)

8.3.21    Netherlands

8.3.21.1    Market size, by product, 2017-2030 (USD Million)

8.3.21.1.1    Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)

8.3.21.1.1.1    Market size, by interferon, 2017-2030 (USD Million)

8.3.21.1.2    Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)

8.3.21.1.2.1    Market size, by erythropoietin, 2017-2030 (USD Million)

8.3.21.1.2.2    Market size, by monoclonal antibodies, 2017-2030 (USD Million)

8.3.21.1.2.3    Market size, by follitropin, 2017-2030 (USD Million)

8.3.21.2    Market size, by application, 2017-2030 (USD Million)

8.3.21.2.1    Market size, by hematology, 2017-2030 (USD Million)

8.3.21.2.2    Market size, by oncology, 2017-2030 (USD Million)

8.3.21.2.2.1    Market size, by leukemia, 2017-2030 (USD Million)

8.3.21.2.3    Market size, by autoimmune disease, 2017-2030 (USD Million)

8.3.21.2.3.1    Market size, by arthritis, 2017-2030 (USD Million)

8.3.21.2.3.2    Market size, by inflammatory bowel disease, 2017-2030 (USD Million)

8.3.21.3    Market size, by manufacturer, 2017-2030 (USD Million)

8.3.21.4    Market size, by technology, 2017-2030 (USD Million)

8.3.22    Norway

8.3.22.1    Market size, by product, 2017-2030 (USD Million)

8.3.22.1.1    Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)

8.3.22.1.1.1    Market size, by interferon, 2017-2030 (USD Million)

8.3.22.1.2    Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)

8.3.22.1.2.1    Market size, by erythropoietin, 2017-2030 (USD Million)

8.3.22.1.2.2    Market size, by monoclonal antibodies, 2017-2030 (USD Million)

8.3.22.1.2.3    Market size, by follitropin, 2017-2030 (USD Million)

8.3.22.2    Market size, by application, 2017-2030 (USD Million)

8.3.22.2.1    Market size, by hematology, 2017-2030 (USD Million)

8.3.22.2.2    Market size, by oncology, 2017-2030 (USD Million)

8.3.22.2.2.1    Market size, by leukemia, 2017-2030 (USD Million)

8.3.22.2.3    Market size, by autoimmune disease, 2017-2030 (USD Million)

8.3.22.2.3.1    Market size, by arthritis, 2017-2030 (USD Million)

8.3.22.2.3.2    Market size, by inflammatory bowel disease, 2017-2030 (USD Million)

8.3.22.3    Market size, by manufacturer, 2017-2030 (USD Million)

8.3.22.4    Market size, by technology, 2017-2030 (USD Million)

8.3.23    Romania

8.3.23.1    Market size, by product, 2017-2030 (USD Million)

8.3.23.1.1    Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)

8.3.23.1.1.1    Market size, by interferon, 2017-2030 (USD Million)

8.3.23.1.2    Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)

8.3.23.1.2.1    Market size, by erythropoietin, 2017-2030 (USD Million)

8.3.23.1.2.2    Market size, by monoclonal antibodies, 2017-2030 (USD Million)

8.3.23.1.2.3    Market size, by follitropin, 2017-2030 (USD Million)

8.3.23.2    Market size, by application, 2017-2030 (USD Million)

8.3.23.2.1    Market size, by hematology, 2017-2030 (USD Million)

8.3.23.2.2    Market size, by oncology, 2017-2030 (USD Million)

8.3.23.2.2.1    Market size, by leukemia, 2017-2030 (USD Million)

8.3.23.2.3    Market size, by autoimmune disease, 2017-2030 (USD Million)

8.3.23.2.3.1    Market size, by arthritis, 2017-2030 (USD Million)

8.3.23.2.3.2    Market size, by inflammatory bowel disease, 2017-2030 (USD Million)

8.3.23.3    Market size, by manufacturer, 2017-2030 (USD Million)

8.3.23.4    Market size, by technology, 2017-2030 (USD Million)

8.3.24    Slovakia

8.3.24.1    Market size, by product, 2017-2030 (USD Million)

8.3.24.1.1    Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)

8.3.24.1.1.1    Market size, by interferon, 2017-2030 (USD Million)

8.3.24.1.2    Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)

8.3.24.1.2.1    Market size, by erythropoietin, 2017-2030 (USD Million)

8.3.24.1.2.2    Market size, by monoclonal antibodies, 2017-2030 (USD Million)

8.3.24.1.2.3    Market size, by follitropin, 2017-2030 (USD Million)

8.3.24.2    Market size, by application, 2017-2030 (USD Million)

8.3.24.2.1    Market size, by hematology, 2017-2030 (USD Million)

8.3.24.2.2    Market size, by oncology, 2017-2030 (USD Million)

8.3.24.2.2.1    Market size, by leukemia, 2017-2030 (USD Million)

8.3.24.2.3    Market size, by autoimmune disease, 2017-2030 (USD Million)

8.3.24.2.3.1    Market size, by arthritis, 2017-2030 (USD Million)

8.3.24.2.3.2    Market size, by inflammatory bowel disease, 2017-2030 (USD Million)

8.3.24.3    Market size, by manufacturer, 2017-2030 (USD Million)

8.3.24.4    Market size, by technology, 2017-2030 (USD Million)

8.3.25    Slovenia

8.3.25.1    Market size, by product, 2017-2030 (USD Million)

8.3.25.1.1    Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)

8.3.25.1.1.1    Market size, by interferon, 2017-2030 (USD Million)

8.3.25.1.2    Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)

8.3.25.1.2.1    Market size, by erythropoietin, 2017-2030 (USD Million)

8.3.25.1.2.2    Market size, by monoclonal antibodies, 2017-2030 (USD Million)

8.3.25.1.2.3    Market size, by follitropin, 2017-2030 (USD Million)

8.3.25.2    Market size, by application, 2017-2030 (USD Million)

8.3.25.2.1    Market size, by hematology, 2017-2030 (USD Million)

8.3.25.2.2    Market size, by oncology, 2017-2030 (USD Million)

8.3.25.2.2.1    Market size, by leukemia, 2017-2030 (USD Million)

8.3.25.2.3    Market size, by autoimmune disease, 2017-2030 (USD Million)

8.3.25.2.3.1    Market size, by arthritis, 2017-2030 (USD Million)

8.3.25.2.3.2    Market size, by inflammatory bowel disease, 2017-2030 (USD Million)

8.3.25.3    Market size, by manufacturer, 2017-2030 (USD Million)

8.3.25.4    Market size, by technology, 2017-2030 (USD Million)

8.3.26    Sweden

8.3.26.1    Market size, by product, 2017-2030 (USD Million)

8.3.26.1.1    Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)

8.3.26.1.1.1    Market size, by interferon, 2017-2030 (USD Million)

8.3.26.1.2    Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)

8.3.26.1.2.1    Market size, by erythropoietin, 2017-2030 (USD Million)

8.3.26.1.2.2    Market size, by monoclonal antibodies, 2017-2030 (USD Million)

8.3.26.1.2.3    Market size, by follitropin, 2017-2030 (USD Million)

8.3.26.2    Market size, by application, 2017-2030 (USD Million)

8.3.26.2.1    Market size, by hematology, 2017-2030 (USD Million)

8.3.26.2.2    Market size, by oncology, 2017-2030 (USD Million)

8.3.26.2.2.1    Market size, by leukemia, 2017-2030 (USD Million)

8.3.26.2.3    Market size, by autoimmune disease, 2017-2030 (USD Million)

8.3.26.2.3.1    Market size, by arthritis, 2017-2030 (USD Million)

8.3.26.2.3.2    Market size, by inflammatory bowel disease, 2017-2030 (USD Million)

8.3.26.3    Market size, by manufacturer, 2017-2030 (USD Million)

8.3.26.4    Market size, by technology, 2017-2030 (USD Million)

8.3.27    Switzerland

8.3.27.1    Market size, by product, 2017-2030 (USD Million)

8.3.27.1.1    Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)

8.3.27.1.1.1    Market size, by interferon, 2017-2030 (USD Million)

8.3.27.1.2    Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)

8.3.27.1.2.1    Market size, by erythropoietin, 2017-2030 (USD Million)

8.3.27.1.2.2    Market size, by monoclonal antibodies, 2017-2030 (USD Million)

8.3.27.1.2.3    Market size, by follitropin, 2017-2030 (USD Million)

8.3.27.2    Market size, by application, 2017-2030 (USD Million)

8.3.27.2.1    Market size, by hematology, 2017-2030 (USD Million)

8.3.27.2.2    Market size, by oncology, 2017-2030 (USD Million)

8.3.27.2.2.1    Market size, by leukemia, 2017-2030 (USD Million)

8.3.27.2.3    Market size, by autoimmune disease, 2017-2030 (USD Million)

8.3.27.2.3.1    Market size, by arthritis, 2017-2030 (USD Million)

8.3.27.2.3.2    Market size, by inflammatory bowel disease, 2017-2030 (USD Million)

8.3.27.3    Market size, by manufacturer, 2017-2030 (USD Million)

8.3.27.4    Market size, by technology, 2017-2030 (USD Million)

8.4    Asia Pacific

8.4.1    Market size, by country, 2017-2030 (USD Million)

8.4.2    Market size, by product, 2017-2030 (USD Million)

8.4.2.1   Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)

8.4.2.1.1    Market size, by interferon, 2017-2030 (USD Million)

8.4.2.2   Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)

8.4.2.2.1    Market size, by erythropoietin, 2017-2030 (USD Million)

8.4.2.2.2    Market size, by monoclonal antibodies, 2017-2030 (USD Million)

8.4.2.2.3    Market size, by follitropin, 2017-2030 (USD Million)

8.4.3    Market size, by application, 2017-2030 (USD Million)

8.4.3.1   Market size, by hematology, 2017-2030 (USD Million)

8.4.3.2   Market size, by oncology, 2017-2030 (USD Million)

8.4.3.2.1    Market size, by leukemia, 2017-2030 (USD Million)

8.4.3.3   Market size, by autoimmune disease, 2017-2030 (USD Million)

8.4.3.3.1    Market size, by arthritis, 2017-2030 (USD Million)

8.4.3.3.2    Market size, by inflammatory bowel disease, 2017-2030 (USD Million)

8.4.4    Market size, by manufacturer, 2017-2030 (USD Million)

8.4.5    Market size, by technology, 2017-2030 (USD Million)

8.4.6    China

8.4.6.1   Market size, by product, 2017-2030 (USD Million)

8.4.6.1.1    Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)

8.4.6.1.1.1    Market size, by interferon, 2017-2030 (USD Million)

8.4.6.1.2    Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)

8.4.6.1.2.1    Market size, by erythropoietin, 2017-2030 (USD Million)

8.4.6.1.2.2    Market size, by monoclonal antibodies, 2017-2030 (USD Million)

8.4.6.1.2.3    Market size, by follitropin, 2017-2030 (USD Million)

8.4.6.2   Market size, by application, 2017-2030 (USD Million)

8.4.6.2.1    Market size, by hematology, 2017-2030 (USD Million)

8.4.6.2.2    Market size, by oncology, 2017-2030 (USD Million)

8.4.6.2.2.1    Market size, by leukemia, 2017-2030 (USD Million)

8.4.6.2.3    Market size, by autoimmune disease, 2017-2030 (USD Million)

8.4.6.2.3.1    Market size, by arthritis, 2017-2030 (USD Million)

8.4.6.2.3.2    Market size, by inflammatory bowel disease, 2017-2030 (USD Million)

8.4.6.3   Market size, by manufacturer, 2017-2030 (USD Million)

8.4.6.4   Market size, by technology, 2017-2030 (USD Million)

8.4.7    Japan

8.4.7.1   Market size, by product, 2017-2030 (USD Million)

8.4.7.1.1    Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)

8.4.7.1.2    Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)

8.4.7.1.2.1    Market size, by erythropoietin, 2017-2030 (USD Million)

8.4.7.1.2.2    Market size, by monoclonal antibodies, 2017-2030 (USD Million)

8.4.7.2   Market size, by application, 2017-2030 (USD Million)

8.4.7.2.1    Market size, by hematology, 2017-2030 (USD Million)

8.4.7.2.2    Market size, by oncology, 2017-2030 (USD Million)

8.4.7.2.2.1    Market size, by leukemia, 2017-2030 (USD Million)

8.4.7.2.3    Market size, by autoimmune disease, 2017-2030 (USD Million)

8.4.7.2.3.1    Market size, by arthritis, 2017-2030 (USD Million)

8.4.7.2.3.2    Market size, by inflammatory bowel disease, 2017-2030 (USD Million)

8.4.7.3   Market size, by manufacturer, 2017-2030 (USD Million)

8.4.7.4   Market size, by technology, 2017-2030 (USD Million)

8.4.8    India

8.4.8.1   Market size, by product, 2017-2030 (USD Million)

8.4.8.1.1    Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)

8.4.8.1.1.1    Market size, by interferon, 2017-2030 (USD Million)

8.4.8.1.2    Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)

8.4.8.1.2.1    Market size, by erythropoietin, 2017-2030 (USD Million)

8.4.8.1.2.2    Market size, by monoclonal antibodies, 2017-2030 (USD Million)

8.4.8.1.2.3    Market size, by follitropin, 2017-2030 (USD Million)

8.4.8.2   Market size, by application, 2017-2030 (USD Million)

8.4.8.2.1    Market size, by hematology, 2017-2030 (USD Million)

8.4.8.2.2    Market size, by oncology, 2017-2030 (USD Million)

8.4.8.2.2.1    Market size, by leukemia, 2017-2030 (USD Million)

8.4.8.2.3    Market size, by autoimmune disease, 2017-2030 (USD Million)

8.4.8.2.3.1    Market size, by arthritis, 2017-2030 (USD Million)

8.4.8.2.3.2    Market size, by inflammatory bowel disease, 2017-2030 (USD Million)

8.4.8.3   Market size, by manufacturer, 2017-2030 (USD Million)

8.4.8.4   Market size, by technology, 2017-2030 (USD Million)

8.4.9    South Korea

8.4.9.1   Market size, by product, 2017-2030 (USD Million)

8.4.9.1.1    Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)

8.4.9.1.2    Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)

8.4.9.1.2.1    Market size, by monoclonal antibodies, 2017-2030 (USD Million)

8.4.9.2   Market size, by application, 2017-2030 (USD Million)

8.4.9.2.1    Market size, by oncology, 2017-2030 (USD Million)

8.4.9.2.1.1    Market size, by leukemia, 2017-2030 (USD Million)

8.4.9.2.2    Market size, by autoimmune disease, 2017-2030 (USD Million)

8.4.9.2.2.1    Market size, by arthritis, 2017-2030 (USD Million)

8.4.9.2.2.2    Market size, by inflammatory bowel disease, 2017-2030 (USD Million)

8.4.9.3   Market size, by manufacturer, 2017-2030 (USD Million)

8.4.9.4   Market size, by technology, 2017-2030 (USD Million)

8.4.10    Australia

8.4.10.1    Market size, by product, 2017-2030 (USD Million)

8.4.10.1.1    Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)

8.4.10.1.2    Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)

8.4.10.1.2.1    Market size, by erythropoietin, 2017-2030 (USD Million)

8.4.10.1.2.2    Market size, by monoclonal antibodies, 2017-2030 (USD Million)

8.4.10.1.2.3    Market size, by follitropin, 2017-2030 (USD Million)

8.4.10.2    Market size, by application, 2017-2030 (USD Million)

8.4.10.2.1    Market size, by hematology, 2017-2030 (USD Million)

8.4.10.2.2    Market size, by oncology, 2017-2030 (USD Million)

8.4.10.2.2.1    Market size, by leukemia, 2017-2030 (USD Million)

8.4.10.2.3    Market size, by autoimmune disease, 2017-2030 (USD Million)

8.4.10.2.3.1    Market size, by arthritis, 2017-2030 (USD Million)

8.4.10.2.3.2    Market size, by inflammatory bowel disease, 2017-2030 (USD Million)

8.4.10.3    Market size, by manufacturer, 2017-2030 (USD Million)

8.4.10.4    Market size, by technology, 2017-2030 (USD Million)

8.4.11    New Zealand

8.4.11.1    Market size, by product, 2017-2030 (USD Million)

8.4.11.1.1    Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)

8.4.11.1.2    Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)

8.4.11.1.2.1    Market size, by erythropoietin, 2017-2030 (USD Million)

8.4.11.2    Market size, by application, 2017-2030 (USD Million)

8.4.11.2.1    Market size, by hematology, 2017-2030 (USD Million)

8.4.11.2.2    Market size, by oncology, 2017-2030 (USD Million)

8.4.11.2.2.1    Market size, by leukemia, 2017-2030 (USD Million)

8.4.11.3    Market size, by manufacturer, 2017-2030 (USD Million)

8.4.11.4    Market size, by technology, 2017-2030 (USD Million)

8.4.12    Singapore

8.4.12.1    Market size, by product, 2017-2030 (USD Million)

8.4.12.1.1    Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)

8.4.12.1.2    Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)

8.4.12.1.2.1    Market size, by monoclonal antibodies, 2017-2030 (USD Million)

8.4.12.2    Market size, by application, 2017-2030 (USD Million)

8.4.12.2.1    Market size, by hematology, 2017-2030 (USD Million)

8.4.12.2.2    Market size, by autoimmune disease, 2017-2030 (USD Million)

8.4.12.2.2.1    Market size, by arthritis, 2017-2030 (USD Million)

8.4.12.2.2.2    Market size, by inflammatory bowel disease, 2017-2030 (USD Million)

8.4.12.3    Market size, by manufacturer, 2017-2030 (USD Million)

8.4.12.4    Market size, by technology, 2017-2030 (USD Million)

8.4.13    Malaysia

8.4.13.1    Market size, by product, 2017-2030 (USD Million)

8.4.13.1.1    Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)

8.4.13.1.2    Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)

8.4.13.1.2.1    Market size, by erythropoietin, 2017-2030 (USD Million)

8.4.13.2    Market size, by application, 2017-2030 (USD Million)

8.4.13.2.1    Market size, by hematology, 2017-2030 (USD Million)

8.4.13.2.2    Market size, by oncology, 2017-2030 (USD Million)

8.4.13.2.2.1    Market size, by leukemia, 2017-2030 (USD Million)

8.4.13.3    Market size, by manufacturer, 2017-2030 (USD Million)

8.4.13.4    Market size, by technology, 2017-2030 (USD Million)

Chapter 9   Company Profiles

9.1    Competitive dashboard, 2021

9.2    Biocon Ltd

9.2.1    Business overview

9.2.2    Financial data

9.2.3    Product landscape

9.2.4    Strategic outlook

9.2.5    SWOT analysis

9.3    Sandoz

9.3.1    Business overview

9.3.2    Financial data

9.3.3    Product landscape

9.3.4    Strategic outlook

9.3.5    SWOT analysis

9.4    Viatris

9.4.1    Business overview

9.4.2    Financial data

9.4.3    Product landscape

9.4.4    Strategic outlook

9.4.5    SWOT analysis

9.5    Bio-Thera Solutions

9.5.1    Business overview

9.5.2    Financial data

9.5.3    Product landscape

9.5.4    Strategic outlook

9.5.5    SWOT analysis

9.6    Pfizer

9.6.1    Business overview

9.6.2    Financial data

9.6.3    Product landscape

9.6.4    Strategic outlook

9.6.5    SWOT analysis

9.7    Dr. Reddy’s Laboratories

9.7.1    Business overview

9.7.2    Financial data

9.7.3    Product landscape

9.7.4    Strategic outlook

9.7.5    SWOT analysis

9.8    Amgen Inc.

9.8.1    Business overview

9.8.2    Financial data

9.8.3    Product landscape

9.8.4    Strategic outlook

9.8.5    SWOT analysis

9.9    Teva Pharmaceuticals

9.9.1    Business overview

9.9.2    Financial data

9.9.3    Product landscape

9.9.4    Strategic outlook

9.9.5    SWOT analysis

9.10    Fresenius Kabi

9.10.1    Business overview

9.10.2    Financial data

9.10.3    Product landscape

9.10.4    Strategic outlook

9.10.5    SWOT analysis

9.11    Coherus Biosciences

9.11.1    Business overview

9.11.2    Financial data

9.11.3    Product landscape

9.11.4    Strategic outlook

9.11.5    SWOT analysis

9.12    Apobiologix

9.12.1    Business overview

9.12.2    Financial data

9.12.3    Product landscape

9.12.4    Strategic outlook

9.12.5    SWOT analysis

9.13    Biocad

9.13.1    Business overview

9.13.2    Financial data

9.13.3    Product landscape

9.13.4    Strategic outlook

9.13.5    SWOT analysis

9.14    Intas Pharma

9.14.1    Business overview

9.14.2    Financial data

9.14.3    Product landscape

9.14.4    Strategic outlook

9.14.5    SWOT analysis

9.15    Reliance Life Sciences

9.15.1    Business overview

9.15.2    Financial data

9.15.3    Product landscape

9.15.4    Strategic outlook

9.15.5    SWOT analysis

9.16    Celltrion

9.16.1    Business overview

9.16.2    Financial data

9.16.3    Product landscape

9.16.4    Strategic outlook

9.16.5    SWOT analysis

9.17    Zydus Cadila

9.17.1    Business overview

9.17.2    Financial data

9.17.3    Product landscape

9.17.4    Strategic outlook

9.17.5    SWOT analysis

9.18    Lupin Pharma

9.18.1    Business overview

9.18.2    Financial data

9.18.3    Product landscape

9.18.4    Strategic outlook

9.18.5    SWOT analysis

9.19    Samsung Bioepis

9.19.1    Business overview

9.19.2    Financial data

9.19.3    Product landscape

9.19.4    Strategic outlook

9.19.5    SWOT analysis
 

Data Tables

TABLE 1.    Biosimilars industry 360⁰ synopsis, 2017-2030

TABLE 2.    Global biosimilars market, 2017-2021 (USD Million)

TABLE 3.    Global biosimilars market, 2022-2030 (USD Million)

TABLE 4.    Global biosimilars market, by product, 2017-2021 (USD Million)

TABLE 5.    Global biosimilars market, by product, 2022-2030 (USD Million)

TABLE 6.    Global biosimilars market, by application, 2017-2021 (USD Million)

TABLE 7.    Global biosimilars market, by application, 2022-2030 (USD Million)

TABLE 8.    Global biosimilars market, by manufacturer, 2017-2021 (USD Million)

TABLE 9.    Global biosimilars market, by manufacturer, 2022-2030 (USD Million)

TABLE 10.    Global biosimilars market, by technology, 2017-2021 (USD Million)

TABLE 11.    Global biosimilars market, by technology, 2022-2030 (USD Million)

TABLE 12.    Global biosimilars market, by region, 2017-2021 (USD Million)

TABLE 13.    Global biosimilars market, by region, 2022-2030 (USD Million)

TABLE 14.    Industry impact forces

TABLE 15.    Amgen biosimilar product pipeline analysis

TABLE 16.    Biocon biosimilar product pipeline analysis

TABLE 17.    Sandoz biosimilar product pipeline analysis

TABLE 18.    Celltrion biosimilar product pipeline analysis

TABLE 19.    Coherus BioSciences biosimilar product pipeline analysis

TABLE 20.    Dr. Reddy's Laboratories biosimilar product pipeline analysis

TABLE 21.    Lupin biosimilar product pipeline analysis

TABLE 22.    Pfizer biosimilar product pipeline analysis

TABLE 23.    Samsung Bioepis biosimilar product pipeline analysis

TABLE 24.    Teva Pharmaceutical biosimilar product pipeline analysis

TABLE 25.    Zydus biosimilar product pipeline analysis

TABLE 26.    U.S. biosimilar approval scenario

TABLE 27.    Canada biosimilar approval scenario

TABLE 28.    Europe biosimilar approval scenario

TABLE 29.    Japan biosimilar approval scenario

TABLE 30.    India biosimilar approval scenario

TABLE 31.    South Korea biosimilar approval scenario

TABLE 32.    Australia biosimilar approval scenario

TABLE 33.    New Zealand biosimilar approval scenario

TABLE 34.    Singapore biosimilar approval scenario

TABLE 35.    Malaysia biosimilar approval scenario

TABLE 36.    Patent expiry scenario

TABLE 37.    Recombinant non-glycosylated proteins market size, by region, 2017-2021 (USD Million)

TABLE 38.    Recombinant non-glycosylated proteins market size, by region, 2022-2030 (USD Million)

TABLE 39.    Human growth hormone market size, by region, 2017-2021 (USD Million)

TABLE 40.    Human growth hormone market size, by region, 2022-2030 (USD Million)

TABLE 41.    Granulocyte colony-stimulating factor (Filgrastim) market size, by region, 2017-2021 (USD Million)

TABLE 42.    Granulocyte colony-stimulating factor (Filgrastim) market size, by region, 2022-2030 (USD Million)

TABLE 43.    Insulin market size, by region, 2017-2021 (USD Million)

TABLE 44.    Insulin market size, by region, 2022-2030 (USD Million)

TABLE 45.    Interferon market size, by region, 2017-2021 (USD Million)

TABLE 46.    Interferon market size, by region, 2022-2030 (USD Million)

TABLE 47.    Alfa market size, by region, 2017-2021 (USD Million)

TABLE 48.    Alfa market size, by region, 2022-2030 (USD Million)

TABLE 49.    Beta market size, by region, 2017-2021 (USD Million)

TABLE 50.    Beta market size, by region, 2022-2030 (USD Million)

TABLE 51.    Recombinant glycosylated proteins market size, by region, 2017-2021 (USD Million)

TABLE 52.    Recombinant glycosylated proteins market size, by region, 2022-2030 (USD Million)

TABLE 53.    Erythropoietin market size, by region, 2017-2021 (USD Million)

TABLE 54.    Erythropoietin market size, by region, 2022-2030 (USD Million)

TABLE 55.    Alfa market size, by region, 2017-2021 (USD Million)

TABLE 56.    Alfa market size, by region, 2022-2030 (USD Million)

TABLE 57.    Zeta market size, by region, 2017-2021 (USD Million)

TABLE 58.    Zeta market size, by region, 2022-2030 (USD Million)

TABLE 59.    Monoclonal antibodies   market size, by region, 2017-2021 (USD Million)

TABLE 60.    Monoclonal antibodies   market size, by region, 2022-2030 (USD Million)

TABLE 61.    Infliximab market size, by region, 2017-2021 (USD Million)

TABLE 62.    Infliximab market size, by region, 2022-2030 (USD Million)

TABLE 63.    Rituximab market size, by region, 2017-2021 (USD Million)

TABLE 64.    Rituximab market size, by region, 2022-2030 (USD Million)

TABLE 65.    Adalimumab market size, by region, 2017-2021 (USD Million)

TABLE 66.    Adalimumab market size, by region, 2022-2030 (USD Million)

TABLE 67.    Trastuzumab market size, by region, 2017-2021 (USD Million)

TABLE 68.    Trastuzumab market size, by region, 2022-2030 (USD Million)

TABLE 69.    Bevacizumab market size, by region, 2017-2021 (USD Million)

TABLE 70.    Bevacizumab market size, by region, 2022-2030 (USD Million)

TABLE 71.    Etanercept market size, by region, 2017-2021 (USD Million)

TABLE 72.    Etanercept market size, by region, 2022-2030 (USD Million)

TABLE 73.    Follitropin   market size, by region, 2017-2021 (USD Million)

TABLE 74.    Follitropin market size, by region, 2022-2030 (USD Million)

TABLE 75.    Alfa market size, by region, 2017-2021 (USD Million)

TABLE 76.    Alfa market size, by region, 2022-2030 (USD Million)

TABLE 77.    Beta market size, by region, 2017-2021 (USD Million)

TABLE 78.    Beta market size, by region, 2022-2030 (USD Million)

TABLE 79.    Low molecular weight heparin market size, by region, 2017-2021 (USD Million)

TABLE 80.    Low molecular weight heparin market size, by region, 2022-2030 (USD Million)

TABLE 81.    Hematology market size, by region, 2017-2021 (USD Million)

TABLE 82.    Hematology market size, by region, 2022-2030 (USD Million)

TABLE 83.    Neutropenia market size, by region, 2017-2021 (USD Million)

TABLE 84.    Neutropenia market size, by region, 2022-2030 (USD Million)

TABLE 85.    Anemia market size, by region, 2017-2021 (USD Million)

TABLE 86.    Anemia market size, by region, 2022-2030 (USD Million)

TABLE 87.    Others market size, by region, 2017-2021 (USD Million)

TABLE 88.    Others market size, by region, 2022-2030 (USD Million)

TABLE 89.    Oncology market size, by region, 2017-2021 (USD Million)

TABLE 90.    Oncology market size, by region, 2022-2030 (USD Million)

TABLE 91.    Lung cancer market size, by region, 2017-2021 (USD Million)

TABLE 92.    Lung cancer market size, by region, 2022-2030 (USD Million)

TABLE 93.    Brain cancer market size, by region, 2017-2021 (USD Million)

TABLE 94.    Brain cancer market size, by region, 2022-2030 (USD Million)

TABLE 95.    Breast cancer market size, by region, 2017-2021 (USD Million)

TABLE 96.    Breast cancer market size, by region, 2022-2030 (USD Million)

TABLE 97.    Cervical cancer market size, by region, 2017-2021 (USD Million)

TABLE 98.    Cervical cancer market size, by region, 2022-2030 (USD Million)

TABLE 99.    Colorectal cancer market size, by region, 2017-2021 (USD Million)

TABLE 100.    Colorectal cancer market size, by region, 2022-2030 (USD Million)

TABLE 101.    Leukemia market size, by region, 2017-2021 (USD Million)

TABLE 102.    Leukemia market size, by region, 2022-2030 (USD Million)

TABLE 103.    Non-Hodgkin lymphoma   (NHL) market size, by region, 2017-2021 (USD Million)

TABLE 104.    Non-Hodgkin lymphoma   (NHL) market size, by region, 2022-2030 (USD Million)

TABLE 105.    Chronic lymphocytic leukemia (CLL) market size, by region, 2017-2021 (USD Million)

TABLE 106.    Chronic lymphocytic leukemia (CLL) market size, by region, 2022-2030 (USD Million)

TABLE 107.    Others market size, by region, 2017-2021 (USD Million)

TABLE 108.    Others market size, by region, 2022-2030 (USD Million)

TABLE 109.    Others market size, by region, 2017-2021 (USD Million)

TABLE 110.    Others market size, by region, 2022-2030 (USD Million)

TABLE 111.    Autoimmune disease market size, by region, 2017-2021 (USD Million)

TABLE 112.    Autoimmune disease market size, by region, 2022-2030 (USD Million)

TABLE 113.    Arthritis market size, by region, 2017-2021 (USD Million)

TABLE 114.    Arthritis market size, by region, 2022-2030 (USD Million)

TABLE 115.    Rheumatoid   arthritis market size, by region, 2017-2021 (USD Million)

TABLE 116.    Rheumatoid   arthritis market size, by region, 2022-2030 (USD Million)

TABLE 117.    Psoriatic arthritis market size, by region, 2017-2021 (USD Million)

TABLE 118.    Psoriatic arthritis market size, by region, 2022-2030 (USD Million)

TABLE 119.    Juvenile arthritis market size, by region, 2017-2021 (USD Million)

TABLE 120.    Juvenile arthritis market size, by region, 2022-2030 (USD Million)

TABLE 121.    Ankylosing spondylitis market size, by region, 2017-2021 (USD Million)

TABLE 122.    Ankylosing spondylitis market size, by region, 2022-2030 (USD Million)

TABLE 123.    Others market size, by region, 2017-2021 (USD Million)

TABLE 124.    Others market size, by region, 2022-2030 (USD Million)

TABLE 125.    Inflammatory bowel disease market size, by region, 2017-2021 (USD Million)

TABLE 126.    Inflammatory bowel disease market size, by region, 2022-2030 (USD Million)

TABLE 127.    Ulcerative colitis market size, by region, 2017-2021 (USD Million)

TABLE 128.    Ulcerative colitis market size, by region, 2022-2030 (USD Million)

TABLE 129.    Crohn's disease market size, by region, 2017-2021 (USD Million)

TABLE 130.    Crohn's disease market size, by region, 2022-2030 (USD Million)

TABLE 131.    Others market size, by region, 2017-2021 (USD Million)

TABLE 132.    Others market size, by region, 2022-2030 (USD Million)

TABLE 133.    Growth hormone deficiency market size, by region, 2017-2021 (USD Million)

TABLE 134.    Growth hormone deficiency market size, by region, 2022-2030 (USD Million)

TABLE 135.    Diabetes market size, by region, 2017-2021 (USD Million)

TABLE 136.    Diabetes market size, by region, 2022-2030 (USD Million)

TABLE 137.    Others market size, by region, 2017-2021 (USD Million)

TABLE 138.    Others market size, by region, 2022-2030 (USD Million)

TABLE 139.    Contract research and manufacturing services market size, by region, 2017-2021 (USD Million)

TABLE 140.    Contract research and manufacturing services market size, by region, 2022-2030 (USD Million)

TABLE 141.    In-house market size, by region, 2017-2021 (USD Million)

TABLE 142.    In-house market size, by region, 2022-2030 (USD Million)

TABLE 143.    Recombinant DNA technology (rDNA technology) market size, by region, 2017-2021 (USD Million)

TABLE 144.    Recombinant DNA technology (rDNA technology) market size, by region, 2022-2030 (USD Million)

TABLE 145.    Monoclonal antibodies (MAb) technology market size, by region, 2017-2021 (USD Million)

TABLE 146.    Monoclonal antibodies (MAb) technology market size, by region, 2022-2030 (USD Million)

TABLE 147.    North America biosimilars market size, by country, 2017-2021 (USD Million)

TABLE 148.    North America biosimilars market size, by country, 2022-2030 (USD Million)

TABLE 149.    North America biosimilars market size, by product, 2017-2021 (USD Million)

TABLE 150.    North America biosimilars market size, by product, 2022-2030 (USD Million)

TABLE 151.    North America biosimilars market size, by recombinant non-glycosylated proteins, 2017-2021 (USD Million)

TABLE 152.    North America biosimilars market size, by recombinant non-glycosylated proteins, 2022-2030 (USD Million)

TABLE 153.    North America biosimilars market size, by recombinant glycosylated proteins, 2017-2021 (USD Million)

TABLE 154.    North America biosimilars market size, by recombinant glycosylated proteins, 2022-2030 (USD Million)

TABLE 155.    North America biosimilars market size, by monoclonal antibodies, 2017-2021 (USD Million)

TABLE 156.    North America biosimilars market size, by monoclonal antibodies, 2022-2030 (USD Million)

TABLE 157.    North America biosimilars market size, by application, 2017-2021 (USD Million)

TABLE 158.    North America biosimilars market size, by application, 2022-2030 (USD Million)

TABLE 159.    North America biosimilars market size, by hematology, 2017-2021 (USD Million)

TABLE 160.    North America biosimilars market size, by hematology, 2022-2030 (USD Million)

TABLE 161.    North America biosimilars market size, by oncology, 2017-2021 (USD Million)

TABLE 162.    North America biosimilars market size, by oncology, 2022-2030 (USD Million)

TABLE 163.    North America biosimilars market size, by leukemia, 2017-2021 (USD Million)

TABLE 164.    North America biosimilars market size, by leukemia, 2022-2030 (USD Million)

TABLE 165.    North America biosimilars market size, by autoimmune disease, 2017-2021 (USD Million)

TABLE 166.    North America biosimilars market size, by autoimmune disease, 2022-2030 (USD Million)

TABLE 167.    North America biosimilars market size, by arthritis, 2017-2021 (USD Million)

TABLE 168.    North America biosimilars market size, by arthritis, 2022-2030 (USD Million)

TABLE 169.    North America biosimilars market size, by inflammatory bowel disease, 2017-2021 (USD Million)

TABLE 170.    North America biosimilars market size, by inflammatory bowel disease, 2022-2030 (USD Million)

TABLE 171.    North America biosimilars market size, by manufacturer, 2017-2021 (USD Million)

TABLE 172.    North America biosimilars market size, by manufacturer, 2022-2030 (USD Million)

TABLE 173.    North America biosimilars market size, by technology, 2017-2021 (USD Million)

TABLE 174.    North America biosimilars market size, by technology, 2022-2030 (USD Million)

TABLE 175.    U.S. biosimilars market size, by product, 2017-2021 (USD Million)

TABLE 176.    U.S. biosimilars market size, by product, 2022-2030 (USD Million)

TABLE 177.    U.S. biosimilars market size, by recombinant non-glycosylated proteins, 2017-2021 (USD Million)

TABLE 178.    U.S. biosimilars market size, by recombinant non-glycosylated proteins, 2022-2030 (USD Million)

TABLE 179.    U.S. biosimilars market size, by recombinant glycosylated proteins, 2017-2021 (USD Million)

TABLE 180.    U.S. biosimilars market size, by recombinant glycosylated proteins, 2022-2030 (USD Million)

TABLE 181.    U.S. biosimilars market size, by monoclonal antibodies, 2017-2021 (USD Million)

TABLE 182.    U.S. biosimilars market size, by monoclonal antibodies, 2022-2030 (USD Million)

TABLE 183.    U.S. biosimilars market size, by application, 2017-2021 (USD Million)

TABLE 184.    U.S. biosimilars market size, by application, 2022-2030 (USD Million)

TABLE 185.    U.S. biosimilars market size, by hematology, 2017-2021 (USD Million)

TABLE 186.    U.S. biosimilars market size, by hematology, 2022-2030 (USD Million)

TABLE 187.    U.S. biosimilars market size, by oncology, 2017-2021 (USD Million)

TABLE 188.    U.S. biosimilars market size, by oncology, 2022-2030 (USD Million)

TABLE 189.    U.S. biosimilars market size, by leukemia, 2017-2021 (USD Million)

TABLE 190.    U.S. biosimilars market size, by leukemia, 2022-2030 (USD Million)

TABLE 191.    U.S. biosimilars market size, by autoimmune disease, 2017-2021 (USD Million)

TABLE 192.    U.S. biosimilars market size, by autoimmune disease, 2022-2030 (USD Million)

TABLE 193.    U.S. biosimilars market size, by arthritis, 2017-2021 (USD Million)

TABLE 194.    U.S. biosimilars market size, by arthritis, 2022-2030 (USD Million)

TABLE 195.    U.S. biosimilars market size, by inflammatory bowel disease, 2017-2021 (USD Million)

TABLE 196.    U.S. biosimilars market size, by inflammatory bowel disease, 2022-2030 (USD Million)

TABLE 197.    U.S. biosimilars market size, by manufacturer, 2017-2021 (USD Million)

TABLE 198.    U.S. biosimilars market size, by manufacturer, 2022-2030 (USD Million)

TABLE 199.    U.S. biosimilars market size, by technology, 2017-2021 (USD Million)

TABLE 200.    U.S. biosimilars market size, by technology, 2022-2030 (USD Million)

TABLE 201.    Canada biosimilars market size, by product, 2017-2021 (USD Million)

TABLE 202.    Canada biosimilars market size, by product, 2022-2030 (USD Million)

TABLE 203.    Canada biosimilars market size, by recombinant non-glycosylated proteins, 2017-2021 (USD Million)

TABLE 204.    Canada biosimilars market size, by recombinant non-glycosylated proteins, 2022-2030 (USD Million)

TABLE 205.    Canada biosimilars market size, by recombinant glycosylated proteins, 2017-2021 (USD Million)

TABLE 206.    Canada biosimilars market size, by recombinant glycosylated proteins, 2022-2030 (USD Million)

TABLE 207.    Canada biosimilars market size, by monoclonal antibodies, 2017-2021 (USD Million)

TABLE 208.    Canada biosimilars market size, by monoclonal antibodies, 2022-2030 (USD Million)

TABLE 209.    Canada biosimilars market size, by application, 2017-2021 (USD Million)

TABLE 210.    Canada biosimilars market size, by application, 2022-2030 (USD Million)

TABLE 211.    Canada biosimilars market size, by hematology, 2017-2021 (USD Million)

TABLE 212.    Canada biosimilars market size, by hematology, 2022-2030 (USD Million)

TABLE 213.    Canada biosimilars market size, by autoimmune disease, 2017-2021 (USD Million)

TABLE 214.    Canada biosimilars market size, by autoimmune disease, 2022-2030 (USD Million)

TABLE 215.    Canada biosimilars market size, by arthritis, 2017-2021 (USD Million)

TABLE 216.    Canada biosimilars market size, by arthritis, 2022-2030 (USD Million)

TABLE 217.    Canada biosimilars market size, by inflammatory bowel disease, 2017-2021 (USD Million)

TABLE 218.    Canada biosimilars market size, by inflammatory bowel disease, 2022-2030 (USD Million)

TABLE 219.    Canada biosimilars market size, by manufacturer, 2017-2021 (USD Million)

TABLE 220.    Canada biosimilars market size, by manufacturer, 2022-2030 (USD Million)

TABLE 221.    Canada biosimilars market size, by technology, 2017-2021 (USD Million)

TABLE 222.    Canada biosimilars market size, by technology, 2022-2030 (USD Million)

TABLE 223.    Europe biosimilars market size, by country, 2017-2021 (USD Million)

TABLE 224.    Europe biosimilars market size, by country, 2022-2030 (USD Million)

TABLE 225.    Europe biosimilars market size, by product, 2017-2021 (USD Million)

TABLE 226.    Europe biosimilars market size, by product, 2022-2030 (USD Million)

TABLE 227.    Europe biosimilars market size, by recombinant non-glycosylated proteins, 2017-2021 (USD Million)

TABLE 228.    Europe biosimilars market size, by recombinant non-glycosylated proteins, 2022-2030 (USD Million)

TABLE 229.    Europe biosimilars market size, by interferon, 2017-2021 (USD Million)

TABLE 230.    Europe biosimilars market size, by interferon, 2022-2030 (USD Million)

TABLE 231.    Europe biosimilars market size, by recombinant glycosylated proteins, 2017-2021 (USD Million)

TABLE 232.    Europe biosimilars market size, by recombinant glycosylated proteins, 2022-2030 (USD Million)

TABLE 233.    Europe biosimilars market size, by erythropoietin, 2017-2021 (USD Million)

TABLE 234.    Europe biosimilars market size, by erythropoietin, 2022-2030 (USD Million)

TABLE 235.    Europe biosimilars market size, by monoclonal antibodies, 2017-2021 (USD Million)

TABLE 236.    Europe biosimilars market size, by monoclonal antibodies, 2022-2030 (USD Million)

TABLE 237.    Europe biosimilars market size, by follitropin, 2017-2021 (USD Million)

TABLE 238.    Europe biosimilars market size, by follitropin, 2022-2030 (USD Million)

TABLE 239.    Europe biosimilars market size, by application, 2017-2021 (USD Million)

TABLE 240.    Europe biosimilars market size, by application, 2022-2030 (USD Million)

TABLE 241.    Europe biosimilars market size, by hematology, 2017-2021 (USD Million)

TABLE 242.    Europe biosimilars market size, by hematology, 2022-2030 (USD Million)

TABLE 243.    Europe biosimilars market size, by oncology, 2017-2021 (USD Million)

TABLE 244.    Europe biosimilars market size, by oncology, 2022-2030 (USD Million)

TABLE 245.    Europe biosimilars market size, by leukemia, 2017-2021 (USD Million)

TABLE 246.    Europe biosimilars market size, by leukemia, 2022-2030 (USD Million)

TABLE 247.    Europe biosimilars market size, by autoimmune disease, 2017-2021 (USD Million)

TABLE 248.    Europe biosimilars market size, by autoimmune disease, 2022-2030 (USD Million)

TABLE 249.    Europe biosimilars market size, by arthritis, 2017-2021 (USD Million)

TABLE 250.    Europe biosimilars market size, by arthritis, 2022-2030 (USD Million)

TABLE 251.    Europe biosimilars market size, by inflammatory bowel disease, 2017-2021 (USD Million)

TABLE 252.    Europe biosimilars market size, by inflammatory bowel disease, 2022-2030 (USD Million)

TABLE 253.    Europe biosimilars market size, by manufacturer, 2017-2021 (USD Million)

TABLE 254.    Europe biosimilars market size, by manufacturer, 2022-2030 (USD Million)

TABLE 255.    Europe biosimilars market size, by technology, 2017-2021 (USD Million)

TABLE 256.    Europe biosimilars market size, by technology, 2022-2030 (USD Million)

TABLE 257.    Germany biosimilars market size, by product, 2017-2021 (USD Million)

TABLE 258.    Germany biosimilars market size, by product, 2022-2030 (USD Million)

TABLE 259.    Germany biosimilars market size, by recombinant non-glycosylated proteins, 2017-2021 (USD Million)

TABLE 260.    Germany biosimilars market size, by recombinant non-glycosylated proteins, 2022-2030 (USD Million)

TABLE 261.    Germany biosimilars market size, by interferon, 2017-2021 (USD Million)

TABLE 262.    Germany biosimilars market size, by interferon, 2022-2030 (USD Million)

TABLE 263.    Germany biosimilars market size, by recombinant glycosylated proteins, 2017-2021 (USD Million)

TABLE 264.    Germany biosimilars market size, by recombinant glycosylated proteins, 2022-2030 (USD Million)

TABLE 265.    Germany biosimilars market size, by erythropoietin, 2017-2021 (USD Million)

TABLE 266.    Germany biosimilars market size, by erythropoietin, 2022-2030 (USD Million)

TABLE 267.    Germany biosimilars market size, by monoclonal antibodies, 2017-2021 (USD Million)

TABLE 268.    Germany biosimilars market size, by monoclonal antibodies, 2022-2030 (USD Million)

TABLE 269.    Germany biosimilars market size, by follitropin, 2017-2021 (USD Million)

TABLE 270.    Germany biosimilars market size, by follitropin, 2022-2030 (USD Million)

TABLE 271.    Germany biosimilars market size, by application, 2017-2021 (USD Million)

TABLE 272.    Germany biosimilars market size, by application, 2022-2030 (USD Million)

TABLE 273.    Germany biosimilars market size, by hematology, 2017-2021 (USD Million)

TABLE 274.    Germany biosimilars market size, by hematology, 2022-2030 (USD Million)

TABLE 275.    Germany biosimilars market size, by oncology, 2017-2021 (USD Million)

TABLE 276.    Germany biosimilars market size, by oncology, 2022-2030 (USD Million)

TABLE 277.    Germany biosimilars market size, by leukemia, 2017-2021 (USD Million)

TABLE 278.    Germany biosimilars market size, by leukemia, 2022-2030 (USD Million)

TABLE 279.    Germany biosimilars market size, by autoimmune disease, 2017-2021 (USD Million)

TABLE 280.    Germany biosimilars market size, by autoimmune disease, 2022-2030 (USD Million)

TABLE 281.    Germany biosimilars market size, by arthritis, 2017-2021 (USD Million)

TABLE 282.    Germany biosimilars market size, by arthritis, 2022-2030 (USD Million)

TABLE 283.    Germany biosimilars market size, by inflammatory bowel disease, 2017-2021 (USD Million)

TABLE 284.    Germany biosimilars market size, by inflammatory bowel disease, 2022-2030 (USD Million)

TABLE 285.    Germany biosimilars market size, by manufacturer, 2017-2021 (USD Million)

TABLE 286.    Germany biosimilars market size, by manufacturer, 2022-2030 (USD Million)

TABLE 287.    Germany biosimilars market size, by technology, 2017-2021 (USD Million)

TABLE 288.    Germany biosimilars market size, by technology, 2022-2030 (USD Million)

TABLE 289.    UK biosimilars market size, by product, 2017-2021 (USD Million)

TABLE 290.    UK biosimilars market size, by product, 2022-2030 (USD Million)

TABLE 291.    UK biosimilars market size, by recombinant non-glycosylated proteins, 2017-2021 (USD Million)

TABLE 292.    UK biosimilars market size, by recombinant non-glycosylated proteins, 2022-2030 (USD Million)

TABLE 293.    UK biosimilars market size, by interferon, 2017-2021 (USD Million)

TABLE 294.    UK biosimilars market size, by interferon, 2022-2030 (USD Million)

TABLE 295.    UK biosimilars market size, by recombinant glycosylated proteins, 2017-2021 (USD Million)

TABLE 296.    UK biosimilars market size, by recombinant glycosylated proteins, 2022-2030 (USD Million)

TABLE 297.    UK biosimilars market size, by erythropoietin, 2017-2021 (USD Million)

TABLE 298.    UK biosimilars market size, by erythropoietin, 2022-2030 (USD Million)

TABLE 299.    UK biosimilars market size, by monoclonal antibodies, 2017-2021 (USD Million)

TABLE 300.    UK biosimilars market size, by monoclonal antibodies, 2022-2030 (USD Million)

TABLE 301.    UK biosimilars market size, by follitropin, 2017-2021 (USD Million)

TABLE 302.    UK biosimilars market size, by follitropin, 2022-2030 (USD Million)

TABLE 303.    UK biosimilars market size, by application, 2017-2021 (USD Million)

TABLE 304.    UK biosimilars market size, by application, 2022-2030 (USD Million)

TABLE 305.    UK biosimilars market size, by hematology, 2017-2021 (USD Million)

TABLE 306.    UK biosimilars market size, by hematology, 2022-2030 (USD Million)

TABLE 307.    UK biosimilars market size, by oncology, 2017-2021 (USD Million)

TABLE 308.    UK biosimilars market size, by oncology, 2022-2030 (USD Million)

TABLE 309.    UK biosimilars market size, by leukemia, 2017-2021 (USD Million)

TABLE 310.    UK biosimilars market size, by leukemia, 2022-2030 (USD Million)

TABLE 311.    UK biosimilars market size, by autoimmune disease, 2017-2021 (USD Million)

TABLE 312.    UK biosimilars market size, by autoimmune disease, 2022-2030 (USD Million)

TABLE 313.    UK biosimilars market size, by arthritis, 2017-2021 (USD Million)

TABLE 314.    UK biosimilars market size, by arthritis, 2022-2030 (USD Million)

TABLE 315.    UK biosimilars market size, by inflammatory bowel disease, 2017-2021 (USD Million)

TABLE 316.    UK biosimilars market size, by inflammatory bowel disease, 2022-2030 (USD Million)

TABLE 317.    UK biosimilars market size, by manufacturer, 2017-2021 (USD Million)

TABLE 318.    UK biosimilars market size, by manufacturer, 2022-2030 (USD Million)

TABLE 319.    UK biosimilars market size, by technology, 2017-2021 (USD Million)

TABLE 320.    UK biosimilars market size, by technology, 2022-2030 (USD Million)

TABLE 321.    France biosimilars market size, by product, 2017-2021 (USD Million)

TABLE 322.    France biosimilars market size, by product, 2022-2030 (USD Million)

TABLE 323.    France biosimilars market size, by recombinant non-glycosylated proteins, 2017-2021 (USD Million)

TABLE 324.    France biosimilars market size, by recombinant non-glycosylated proteins, 2022-2030 (USD Million)

TABLE 325.    France biosimilars market size, by interferon, 2017-2021 (USD Million)

TABLE 326.    France biosimilars market size, by interferon, 2022-2030 (USD Million)

TABLE 327.    France biosimilars market size, by recombinant glycosylated proteins, 2017-2021 (USD Million)

TABLE 328.    France biosimilars market size, by recombinant glycosylated proteins, 2022-2030 (USD Million)

TABLE 329.    France biosimilars market size, by erythropoietin, 2017-2021 (USD Million)

TABLE 330.    France biosimilars market size, by erythropoietin, 2022-2030 (USD Million)

TABLE 331.    France biosimilars market size, by monoclonal antibodies, 2017-2021 (USD Million)

TABLE 332.    France biosimilars market size, by monoclonal antibodies, 2022-2030 (USD Million)

TABLE 333.    France biosimilars market size, by follitropin, 2017-2021 (USD Million)

TABLE 334.    France biosimilars market size, by follitropin, 2022-2030 (USD Million)

TABLE 335.    France biosimilars market size, by application, 2017-2021 (USD Million)

TABLE 336.    France biosimilars market size, by application, 2022-2030 (USD Million)

TABLE 337.    France biosimilars market size, by hematology, 2017-2021 (USD Million)

TABLE 338.    France biosimilars market size, by hematology, 2022-2030 (USD Million)

TABLE 339.    France biosimilars market size, by oncology, 2017-2021 (USD Million)

TABLE 340.    France biosimilars market size, by oncology, 2022-2030 (USD Million)

TABLE 341.    France biosimilars market size, by leukemia, 2017-2021 (USD Million)

TABLE 342.    France biosimilars market size, by leukemia, 2022-2030 (USD Million)

TABLE 343.    France biosimilars market size, by autoimmune disease, 2017-2021 (USD Million)

TABLE 344.    France biosimilars market size, by autoimmune disease, 2022-2030 (USD Million)

TABLE 345.    France biosimilars market size, by arthritis, 2017-2021 (USD Million)

TABLE 346.    France biosimilars market size, by arthritis, 2022-2030 (USD Million)

TABLE 347.    France biosimilars market size, by inflammatory bowel disease, 2017-2021 (USD Million)

TABLE 348.    France biosimilars market size, by inflammatory bowel disease, 2022-2030 (USD Million)

TABLE 349.    France biosimilars market size, by manufacturer, 2017-2021 (USD Million)

TABLE 350.    France biosimilars market size, by manufacturer, 2022-2030 (USD Million)

TABLE 351.    France biosimilars market size, by technology, 2017-2021 (USD Million)

TABLE 352.    France biosimilars market size, by technology, 2022-2030 (USD Million)

TABLE 353.    Spain biosimilars market size, by product, 2017-2021 (USD Million)

TABLE 354.    Spain biosimilars market size, by product, 2022-2030 (USD Million)

TABLE 355.    Spain biosimilars market size, by recombinant non-glycosylated proteins, 2017-2021 (USD Million)

TABLE 356.    Spain biosimilars market size, by recombinant non-glycosylated proteins, 2022-2030 (USD Million)

TABLE 357.    Spain biosimilars market size, by interferon, 2017-2021 (USD Million)

TABLE 358.    Spain biosimilars market size, by interferon, 2022-2030 (USD Million)

TABLE 359.    Spain biosimilars market size, by recombinant glycosylated proteins, 2017-2021 (USD Million)

TABLE 360.    Spain biosimilars market size, by recombinant glycosylated proteins, 2022-2030 (USD Million)

TABLE 361.    Spain biosimilars market size, by erythropoietin, 2017-2021 (USD Million)

TABLE 362.    Spain biosimilars market size, by erythropoietin, 2022-2030 (USD Million)

TABLE 363.    Spain biosimilars market size, by monoclonal antibodies, 2017-2021 (USD Million)

TABLE 364.    Spain biosimilars market size, by monoclonal antibodies, 2022-2030 (USD Million)

TABLE 365.    Spain biosimilars market size, by follitropin, 2017-2021 (USD Million)

TABLE 366.    Spain biosimilars market size, by follitropin, 2022-2030 (USD Million)

TABLE 367.    Spain biosimilars market size, by application, 2017-2021 (USD Million)

TABLE 368.    Spain biosimilars market size, by application, 2022-2030 (USD Million)

TABLE 369.    Spain biosimilars market size, by hematology, 2017-2021 (USD Million)

TABLE 370.    Spain biosimilars market size, by hematology, 2022-2030 (USD Million)

TABLE 371.    Spain biosimilars market size, by oncology, 2017-2021 (USD Million)

TABLE 372.    Spain biosimilars market size, by oncology, 2022-2030 (USD Million)

TABLE 373.    Spain biosimilars market size, by leukemia, 2017-2021 (USD Million)

TABLE 374.    Spain biosimilars market size, by leukemia, 2022-2030 (USD Million)

TABLE 375.    Spain biosimilars market size, by autoimmune disease, 2017-2021 (USD Million)

TABLE 376.    Spain biosimilars market size, by autoimmune disease, 2022-2030 (USD Million)

TABLE 377.    Spain biosimilars market size, by arthritis, 2017-2021 (USD Million)

TABLE 378.    Spain biosimilars market size, by arthritis, 2022-2030 (USD Million)

TABLE 379.    Spain biosimilars market size, by inflammatory bowel disease, 2017-2021 (USD Million)

TABLE 380.    Spain biosimilars market size, by inflammatory bowel disease, 2022-2030 (USD Million)

TABLE 381.    Spain biosimilars market size, by manufacturer, 2017-2021 (USD Million)

TABLE 382.    Spain biosimilars market size, by manufacturer, 2022-2030 (USD Million)

TABLE 383.    Spain biosimilars market size, by technology, 2017-2021 (USD Million)

TABLE 384.    Spain biosimilars market size, by technology, 2022-2030 (USD Million)

TABLE 385.    Italy biosimilars market size, by product, 2017-2021 (USD Million)

TABLE 386.    Italy biosimilars market size, by product, 2022-2030 (USD Million)

TABLE 387.    Italy biosimilars market size, by recombinant non-glycosylated proteins, 2017-2021 (USD Million)

TABLE 388.    Italy biosimilars market size, by recombinant non-glycosylated proteins, 2022-2030 (USD Million)

TABLE 389.    Italy biosimilars market size, by interferon, 2017-2021 (USD Million)

TABLE 390.    Italy biosimilars market size, by interferon, 2022-2030 (USD Million)

TABLE 391.    Italy biosimilars market size, by recombinant glycosylated proteins, 2017-2021 (USD Million)

TABLE 392.    Italy biosimilars market size, by recombinant glycosylated proteins, 2022-2030 (USD Million)

TABLE 393.    Italy biosimilars market size, by erythropoietin, 2017-2021 (USD Million)

TABLE 394.    Italy biosimilars market size, by erythropoietin, 2022-2030 (USD Million)

TABLE 395.    Italy biosimilars market size, by monoclonal antibodies, 2017-2021 (USD Million)

TABLE 396.    Italy biosimilars market size, by monoclonal antibodies, 2022-2030 (USD Million)

TABLE 397.    Italy biosimilars market size, by follitropin, 2017-2021 (USD Million)

TABLE 398.    Italy biosimilars market size, by follitropin, 2022-2030 (USD Million)

TABLE 399.    Italy biosimilars market size, by application, 2017-2021 (USD Million)

TABLE 400.    Italy biosimilars market size, by application, 2022-2030 (USD Million)

TABLE 401.    Italy biosimilars market size, by hematology, 2017-2021 (USD Million)

TABLE 402.    Italy biosimilars market size, by hematology, 2022-2030 (USD Million)

TABLE 403.    Italy biosimilars market size, by oncology, 2017-2021 (USD Million)

TABLE 404.    Italy biosimilars market size, by oncology, 2022-2030 (USD Million)

TABLE 405.    Italy biosimilars market size, by leukemia, 2017-2021 (USD Million)

TABLE 406.    Italy biosimilars market size, by leukemia, 2022-2030 (USD Million)

TABLE 407.    Italy biosimilars market size, by autoimmune disease, 2017-2021 (USD Million)

TABLE 408.    Italy biosimilars market size, by autoimmune disease, 2022-2030 (USD Million)

TABLE 409.    Italy biosimilars market size, by arthritis, 2017-2021 (USD Million)

TABLE 410.    Italy biosimilars market size, by arthritis, 2022-2030 (USD Million)

TABLE 411.    Italy biosimilars market size, by inflammatory bowel disease, 2017-2021 (USD Million)

TABLE 412.    Italy biosimilars market size, by inflammatory bowel disease, 2022-2030 (USD Million)

TABLE 413.    Germany biosimilars market size, by manufacturer, 2017-2021 (USD Million)

TABLE 414.    Italy biosimilars market size, by manufacturer, 2022-2030 (USD Million)

TABLE 415.    Italy biosimilars market size, by technology, 2017-2021 (USD Million)

TABLE 416.    Italy biosimilars market size, by technology, 2022-2030 (USD Million)

TABLE 417.    Turkey biosimilars market size, by product, 2017-2021 (USD Million)

TABLE 418.    Turkey biosimilars market size, by product, 2022-2030 (USD Million)

TABLE 419.    Turkey biosimilars market size, by recombinant non-glycosylated proteins, 2017-2021 (USD Million)

TABLE 420.    Turkey biosimilars market size, by recombinant non-glycosylated proteins, 2022-2030 (USD Million)

TABLE 421.    Turkey biosimilars market size, by interferon, 2017-2021 (USD Million)

TABLE 422.    Turkey biosimilars market size, by interferon, 2022-2030 (USD Million)

TABLE 423.    Turkey biosimilars market size, by recombinant glycosylated proteins, 2017-2021 (USD Million)

TABLE 424.    Turkey biosimilars market size, by recombinant glycosylated proteins, 2022-2030 (USD Million)

TABLE 425.    Turkey biosimilars market size, by erythropoietin, 2017-2021 (USD Million)

TABLE 426.    Turkey biosimilars market size, by erythropoietin, 2022-2030 (USD Million)

TABLE 427.    Turkey biosimilars market size, by monoclonal antibodies, 2017-2021 (USD Million)

TABLE 428.    Turkey biosimilars market size, by monoclonal antibodies, 2022-2030 (USD Million)

TABLE 429.    Turkey biosimilars market size, by follitropin, 2017-2021 (USD Million)

TABLE 430.    Turkey biosimilars market size, by follitropin, 2022-2030 (USD Million)

TABLE 431.    Turkey biosimilars market size, by application, 2017-2021 (USD Million)

TABLE 432.    Turkey biosimilars market size, by application, 2022-2030 (USD Million)

TABLE 433.    Turkey biosimilars market size, by hematology, 2017-2021 (USD Million)

TABLE 434.    Turkey biosimilars market size, by hematology, 2022-2030 (USD Million)

TABLE 435.    Turkey biosimilars market size, by oncology, 2017-2021 (USD Million)

TABLE 436.    Turkey biosimilars market size, by oncology, 2022-2030 (USD Million)

TABLE 437.    Turkey biosimilars market size, by leukemia, 2017-2021 (USD Million)

TABLE 438.    Turkey biosimilars market size, by leukemia, 2022-2030 (USD Million)

TABLE 439.    Turkey biosimilars market size, by autoimmune disease, 2017-2021 (USD Million)

TABLE 440.    Turkey biosimilars market size, by autoimmune disease, 2022-2030 (USD Million)

TABLE 441.    Turkey biosimilars market size, by arthritis, 2017-2021 (USD Million)

TABLE 442.    Turkey biosimilars market size, by arthritis, 2022-2030 (USD Million)

TABLE 443.    Turkey biosimilars market size, by inflammatory bowel disease, 2017-2021 (USD Million)

TABLE 444.    Turkey biosimilars market size, by inflammatory bowel disease, 2022-2030 (USD Million)

TABLE 445.    Turkey biosimilars market size, by manufacturer, 2017-2021 (USD Million)

TABLE 446.    Germany biosimilars market size, by manufacturer, 2022-2030 (USD Million)

TABLE 447.    Turkey biosimilars market size, by technology, 2017-2021 (USD Million)

TABLE 448.    Turkey biosimilars market size, by technology, 2022-2030 (USD Million)

TABLE 449.    Austria biosimilars market size, by product, 2017-2021 (USD Million)

TABLE 450.    Austria biosimilars market size, by product, 2022-2030 (USD Million)

TABLE 451.    Austria biosimilars market size, by recombinant non-glycosylated proteins, 2017-2021 (USD Million)

TABLE 452.    Austria biosimilars market size, by recombinant non-glycosylated proteins, 2022-2030 (USD Million)

TABLE 453.    Austria biosimilars market size, by interferon, 2017-2021 (USD Million)

TABLE 454.    Austria biosimilars market size, by interferon, 2022-2030 (USD Million)

TABLE 455.    Austria biosimilars market size, by recombinant glycosylated proteins, 2017-2021 (USD Million)

TABLE 456.    Austria biosimilars market size, by recombinant glycosylated proteins, 2022-2030 (USD Million)

TABLE 457.    Austria biosimilars market size, by erythropoietin, 2017-2021 (USD Million)

TABLE 458.    Austria biosimilars market size, by erythropoietin, 2022-2030 (USD Million)

TABLE 459.    Austria biosimilars market size, by monoclonal antibodies, 2017-2021 (USD Million)

TABLE 460.    Austria biosimilars market size, by monoclonal antibodies, 2022-2030 (USD Million)

TABLE 461.    Austria biosimilars market size, by follitropin, 2017-2021 (USD Million)

TABLE 462.    Austria biosimilars market size, by follitropin, 2022-2030 (USD Million)

TABLE 463.    Austria biosimilars market size, by application, 2017-2021 (USD Million)

TABLE 464.    Austria biosimilars market size, by application, 2022-2030 (USD Million)

TABLE 465.    Austria biosimilars market size, by hematology, 2017-2021 (USD Million)

TABLE 466.    Austria biosimilars market size, by hematology, 2022-2030 (USD Million)

TABLE 467.    Austria biosimilars market size, by oncology, 2017-2021 (USD Million)

TABLE 468.    Austria biosimilars market size, by oncology, 2022-2030 (USD Million)

TABLE 469.    Austria biosimilars market size, by leukemia, 2017-2021 (USD Million)

TABLE 470.    Austria biosimilars market size, by leukemia, 2022-2030 (USD Million)

TABLE 471.    Austria biosimilars market size, by autoimmune disease, 2017-2021 (USD Million)

TABLE 472.    Austria biosimilars market size, by autoimmune disease, 2022-2030 (USD Million)

TABLE 473.    Austria biosimilars market size, by arthritis, 2017-2021 (USD Million)

TABLE 474.    Austria biosimilars market size, by arthritis, 2022-2030 (USD Million)

TABLE 475.    Austria biosimilars market size, by inflammatory bowel disease, 2017-2021 (USD Million)

TABLE 476.    Austria biosimilars market size, by inflammatory bowel disease, 2022-2030 (USD Million)

TABLE 477.    Austria biosimilars market size, by manufacturer, 2017-2021 (USD Million)

TABLE 478.    Austria biosimilars market size, by manufacturer, 2022-2030 (USD Million)

TABLE 479.    Austria biosimilars market size, by technology, 2017-2021 (USD Million)

TABLE 480.    Austria biosimilars market size, by technology, 2022-2030 (USD Million)

TABLE 481.    Belgium biosimilars market size, by product, 2017-2021 (USD Million)

TABLE 482.    Belgium biosimilars market size, by product, 2022-2030 (USD Million)

TABLE 483.    Belgium biosimilars market size, by recombinant non-glycosylated proteins, 2017-2021 (USD Million)

TABLE 484.    Belgium biosimilars market size, by recombinant non-glycosylated proteins, 2022-2030 (USD Million)

TABLE 485.    Belgium biosimilars market size, by interferon, 2017-2021 (USD Million)

TABLE 486.    Belgium biosimilars market size, by interferon, 2022-2030 (USD Million)

TABLE 487.    Belgium biosimilars market size, by recombinant glycosylated proteins, 2017-2021 (USD Million)

TABLE 488.    Belgium biosimilars market size, by recombinant glycosylated proteins, 2022-2030 (USD Million)

TABLE 489.    Belgium biosimilars market size, by erythropoietin, 2017-2021 (USD Million)

TABLE 490.    Belgium biosimilars market size, by erythropoietin, 2022-2030 (USD Million)

TABLE 491.    Belgium biosimilars market size, by monoclonal antibodies, 2017-2021 (USD Million)

TABLE 492.    Belgium biosimilars market size, by monoclonal antibodies, 2022-2030 (USD Million)

TABLE 493.    Belgium biosimilars market size, by follitropin, 2017-2021 (USD Million)

TABLE 494.    Belgium biosimilars market size, by follitropin, 2022-2030 (USD Million)

TABLE 495.    Belgium biosimilars market size, by application, 2017-2021 (USD Million)

TABLE 496.    Belgium biosimilars market size, by application, 2022-2030 (USD Million)

TABLE 497.    Belgium biosimilars market size, by hematology, 2017-2021 (USD Million)

TABLE 498.    Belgium biosimilars market size, by hematology, 2022-2030 (USD Million)

TABLE 499.    Belgium biosimilars market size, by oncology, 2017-2021 (USD Million)

TABLE 500.    Belgium biosimilars market size, by oncology, 2022-2030 (USD Million)

TABLE 501.    Belgium biosimilars market size, by leukemia, 2017-2021 (USD Million)

TABLE 502.    Belgium biosimilars market size, by leukemia, 2022-2030 (USD Million)

TABLE 503.    Belgium biosimilars market size, by autoimmune disease, 2017-2021 (USD Million)

TABLE 504.    Belgium biosimilars market size, by autoimmune disease, 2022-2030 (USD Million)

TABLE 505.    Belgium biosimilars market size, by arthritis, 2017-2021 (USD Million)

TABLE 506.    Belgium biosimilars market size, by arthritis, 2022-2030 (USD Million)

TABLE 507.    Belgium biosimilars market size, by inflammatory bowel disease, 2017-2021 (USD Million)

TABLE 508.    Belgium biosimilars market size, by inflammatory bowel disease, 2022-2030 (USD Million)

TABLE 509.    Belgium biosimilars market size, by manufacturer, 2017-2021 (USD Million)

TABLE 510.    Belgium biosimilars market size, by manufacturer, 2022-2030 (USD Million)

TABLE 511.    Belgium biosimilars market size, by technology, 2017-2021 (USD Million)

TABLE 512.    Belgium biosimilars market size, by technology, 2022-2030 (USD Million)

TABLE 513.    Bulgaria biosimilars market size, by product, 2017-2021 (USD Million)

TABLE 514.    Bulgaria biosimilars market size, by product, 2022-2030 (USD Million)

TABLE 515.    Bulgaria biosimilars market size, by recombinant non-glycosylated proteins, 2017-2021 (USD Million)

TABLE 516.    Bulgaria biosimilars market size, by recombinant non-glycosylated proteins, 2022-2030 (USD Million)

TABLE 517.    Bulgaria biosimilars market size, by interferon, 2017-2021 (USD Million)

TABLE 518.    Bulgaria biosimilars market size, by interferon, 2022-2030 (USD Million)

TABLE 519.    Bulgaria biosimilars market size, by recombinant glycosylated proteins, 2017-2021 (USD Million)

TABLE 520.    Bulgaria biosimilars market size, by recombinant glycosylated proteins, 2022-2030 (USD Million)

TABLE 521.    Bulgaria biosimilars market size, by erythropoietin, 2017-2021 (USD Million)

TABLE 522.    Bulgaria biosimilars market size, by erythropoietin, 2022-2030 (USD Million)

TABLE 523.    Bulgaria biosimilars market size, by monoclonal antibodies, 2017-2021 (USD Million)

TABLE 524.    Bulgaria biosimilars market size, by monoclonal antibodies, 2022-2030 (USD Million)

TABLE 525.    Bulgaria biosimilars market size, by follitropin, 2017-2021 (USD Million)

TABLE 526.    Bulgaria biosimilars market size, by follitropin, 2022-2030 (USD Million)

TABLE 527.    Bulgaria biosimilars market size, by application, 2017-2021 (USD Million)

TABLE 528.    Bulgaria biosimilars market size, by application, 2022-2030 (USD Million)

TABLE 529.    Bulgaria biosimilars market size, by hematology, 2017-2021 (USD Million)

TABLE 530.    Bulgaria biosimilars market size, by hematology, 2022-2030 (USD Million)

TABLE 531.    Bulgaria biosimilars market size, by oncology, 2017-2021 (USD Million)

TABLE 532.    Bulgaria biosimilars market size, by oncology, 2022-2030 (USD Million)

TABLE 533.    Bulgaria biosimilars market size, by leukemia, 2017-2021 (USD Million)

TABLE 534.    Bulgaria biosimilars market size, by leukemia, 2022-2030 (USD Million)

TABLE 535.    Bulgaria biosimilars market size, by autoimmune disease, 2017-2021 (USD Million)

TABLE 536.    Bulgaria biosimilars market size, by autoimmune disease, 2022-2030 (USD Million)

TABLE 537.    Bulgaria biosimilars market size, by arthritis, 2017-2021 (USD Million)

TABLE 538.    Bulgaria biosimilars market size, by arthritis, 2022-2030 (USD Million)

TABLE 539.    Bulgaria biosimilars market size, by inflammatory bowel disease, 2017-2021 (USD Million)

TABLE 540.    Bulgaria biosimilars market size, by inflammatory bowel disease, 2022-2030 (USD Million)

TABLE 541.    Bulgaria biosimilars market size, by manufacturer, 2017-2021 (USD Million)

TABLE 542.    Bulgaria biosimilars market size, by manufacturer, 2022-2030 (USD Million)

TABLE 543.    Bulgaria biosimilars market size, by technology, 2017-2021 (USD Million)

TABLE 544.    Bulgaria biosimilars market size, by technology, 2022-2030 (USD Million)

TABLE 545.    Czech Republic biosimilars market size, by product, 2017-2021 (USD Million)

TABLE 546.    Czech Republic biosimilars market size, by product, 2022-2030 (USD Million)

TABLE 547.    Czech Republic biosimilars market size, by recombinant non-glycosylated proteins, 2017-2021 (USD Million)

TABLE 548.    Czech Republic biosimilars market size, by recombinant non-glycosylated proteins, 2022-2030 (USD Million)

TABLE 549.    Czech Republic biosimilars market size, by interferon, 2017-2021 (USD Million)

TABLE 550.    Czech Republic biosimilars market size, by interferon, 2022-2030 (USD Million)

TABLE 551.    Czech Republic biosimilars market size, by recombinant glycosylated proteins, 2017-2021 (USD Million)

TABLE 552.    Czech Republic biosimilars market size, by recombinant glycosylated proteins, 2022-2030 (USD Million)

TABLE 553.    Czech Republic biosimilars market size, by erythropoietin, 2017-2021 (USD Million)

TABLE 554.    Czech Republic biosimilars market size, by erythropoietin, 2022-2030 (USD Million)

TABLE 555.    Czech Republic biosimilars market size, by monoclonal antibodies, 2017-2021 (USD Million)

TABLE 556.    Czech Republic biosimilars market size, by monoclonal antibodies, 2022-2030 (USD Million)

TABLE 557.    Czech Republic biosimilars market size, by follitropin, 2017-2021 (USD Million)

TABLE 558.    Czech Republic biosimilars market size, by follitropin, 2022-2030 (USD Million)

TABLE 559.    Czech Republic biosimilars market size, by application, 2017-2021 (USD Million)

TABLE 560.    Czech Republic biosimilars market size, by application, 2022-2030 (USD Million)

TABLE 561.    Czech Republic biosimilars market size, by hematology, 2017-2021 (USD Million)

TABLE 562.    Czech Republic biosimilars market size, by hematology, 2022-2030 (USD Million)

TABLE 563.    Czech Republic biosimilars market size, by oncology, 2017-2021 (USD Million)

TABLE 564.    Czech Republic biosimilars market size, by oncology, 2022-2030 (USD Million)

TABLE 565.    Czech Republic biosimilars market size, by leukemia, 2017-2021 (USD Million)

TABLE 566.    Czech Republic biosimilars market size, by leukemia, 2022-2030 (USD Million)

TABLE 567.    Czech Republic biosimilars market size, by autoimmune disease, 2017-2021 (USD Million)

TABLE 568.    Czech Republic biosimilars market size, by autoimmune disease, 2022-2030 (USD Million)

TABLE 569.    Czech Republic biosimilars market size, by arthritis, 2017-2021 (USD Million)

TABLE 570.    Czech Republic biosimilars market size, by arthritis, 2022-2030 (USD Million)

TABLE 571.    Czech Republic biosimilars market size, by inflammatory bowel disease, 2017-2021 (USD Million)

TABLE 572.    Czech Republic biosimilars market size, by inflammatory bowel disease, 2022-2030 (USD Million)

TABLE 573.    Czech Republic biosimilars market size, by manufacturer, 2017-2021 (USD Million)

TABLE 574.    Czech Republic biosimilars market size, by manufacturer, 2022-2030 (USD Million)

TABLE 575.    Czech Republic biosimilars market size, by technology, 2017-2021 (USD Million)

TABLE 576.    Czech Republic biosimilars market size, by technology, 2022-2030 (USD Million)

TABLE 577.    Denmark biosimilars market size, by product, 2017-2021 (USD Million)

TABLE 578.    Denmark biosimilars market size, by product, 2022-2030 (USD Million)

TABLE 579.    Denmark biosimilars market size, by recombinant non-glycosylated proteins, 2017-2021 (USD Million)

TABLE 580.    Denmark biosimilars market size, by recombinant non-glycosylated proteins, 2022-2030 (USD Million)

TABLE 581.    Denmark biosimilars market size, by interferon, 2017-2021 (USD Million)

TABLE 582.    Denmark biosimilars market size, by interferon, 2022-2030 (USD Million)

TABLE 583.    Denmark biosimilars market size, by recombinant glycosylated proteins, 2017-2021 (USD Million)

TABLE 584.    Denmark biosimilars market size, by recombinant glycosylated proteins, 2022-2030 (USD Million)

TABLE 585.    Denmark biosimilars market size, by erythropoietin, 2017-2021 (USD Million)

TABLE 586.    Denmark biosimilars market size, by erythropoietin, 2022-2030 (USD Million)

TABLE 587.    Denmark biosimilars market size, by monoclonal antibodies, 2017-2021 (USD Million)

TABLE 588.    Denmark biosimilars market size, by monoclonal antibodies, 2022-2030 (USD Million)

TABLE 589.    Denmark biosimilars market size, by follitropin, 2017-2021 (USD Million)

TABLE 590.    Denmark biosimilars market size, by follitropin, 2022-2030 (USD Million)

TABLE 591.    Denmark biosimilars market size, by application, 2017-2021 (USD Million)

TABLE 592.    Denmark biosimilars market size, by application, 2022-2030 (USD Million)

TABLE 593.    Denmark biosimilars market size, by hematology, 2017-2021 (USD Million)

TABLE 594.    Denmark biosimilars market size, by hematology, 2022-2030 (USD Million)

TABLE 595.    Denmark biosimilars market size, by oncology, 2017-2021 (USD Million)

TABLE 596.    Denmark biosimilars market size, by oncology, 2022-2030 (USD Million)

TABLE 597.    Denmark biosimilars market size, by leukemia, 2017-2021 (USD Million)

TABLE 598.    Denmark biosimilars market size, by leukemia, 2022-2030 (USD Million)

TABLE 599.    Denmark biosimilars market size, by autoimmune disease, 2017-2021 (USD Million)

TABLE 600.    Denmark biosimilars market size, by autoimmune disease, 2022-2030 (USD Million)

TABLE 601.    Denmark biosimilars market size, by arthritis, 2017-2021 (USD Million)

TABLE 602.    Denmark biosimilars market size, by arthritis, 2022-2030 (USD Million)

TABLE 603.    Denmark biosimilars market size, by inflammatory bowel disease, 2017-2021 (USD Million)

TABLE 604.    Denmark biosimilars market size, by inflammatory bowel disease, 2022-2030 (USD Million)

TABLE 605.    Denmark biosimilars market size, by manufacturer, 2017-2021 (USD Million)

TABLE 606.    Denmark biosimilars market size, by manufacturer, 2022-2030 (USD Million)

TABLE 607.    Denmark biosimilars market size, by technology, 2017-2021 (USD Million)

TABLE 608.    Denmark biosimilars market size, by technology, 2022-2030 (USD Million)

TABLE 609.    Finland biosimilars market size, by product, 2017-2021 (USD Million)

TABLE 610.    Finland biosimilars market size, by product, 2022-2030 (USD Million)

TABLE 611.    Finland biosimilars market size, by recombinant non-glycosylated proteins, 2017-2021 (USD Million)

TABLE 612.    Finland biosimilars market size, by recombinant non-glycosylated proteins, 2022-2030 (USD Million)

TABLE 613.    Finland biosimilars market size, by interferon, 2017-2021 (USD Million)

TABLE 614.    Finland biosimilars market size, by interferon, 2022-2030 (USD Million)

TABLE 615.    Finland biosimilars market size, by recombinant glycosylated proteins, 2017-2021 (USD Million)

TABLE 616.    Finland biosimilars market size, by recombinant glycosylated proteins, 2022-2030 (USD Million)

TABLE 617.    Finland biosimilars market size, by erythropoietin, 2017-2021 (USD Million)

TABLE 618.    Finland biosimilars market size, by erythropoietin, 2022-2030 (USD Million)

TABLE 619.    Finland biosimilars market size, by monoclonal antibodies, 2017-2021 (USD Million)

TABLE 620.    Finland biosimilars market size, by monoclonal antibodies, 2022-2030 (USD Million)

TABLE 621.    Finland biosimilars market size, by follitropin, 2017-2021 (USD Million)

TABLE 622.    Finland biosimilars market size, by follitropin, 2022-2030 (USD Million)

TABLE 623.    Finland biosimilars market size, by application, 2017-2021 (USD Million)

TABLE 624.    Finland biosimilars market size, by application, 2022-2030 (USD Million)

TABLE 625.    Finland biosimilars market size, by hematology, 2017-2021 (USD Million)

TABLE 626.    Finland biosimilars market size, by hematology, 2022-2030 (USD Million)

TABLE 627.    Finland biosimilars market size, by oncology, 2017-2021 (USD Million)

TABLE 628.    Finland biosimilars market size, by oncology, 2022-2030 (USD Million)

TABLE 629.    Finland biosimilars market size, by leukemia, 2017-2021 (USD Million)

TABLE 630.    Finland biosimilars market size, by leukemia, 2022-2030 (USD Million)

TABLE 631.    Finland biosimilars market size, by autoimmune disease, 2017-2021 (USD Million)

TABLE 632.    Finland biosimilars market size, by autoimmune disease, 2022-2030 (USD Million)

TABLE 633.    Finland biosimilars market size, by arthritis, 2017-2021 (USD Million)

TABLE 634.    Finland biosimilars market size, by arthritis, 2022-2030 (USD Million)

TABLE 635.    Finland biosimilars market size, by inflammatory bowel disease, 2017-2021 (USD Million)

TABLE 636.    Finland biosimilars market size, by inflammatory bowel disease, 2022-2030 (USD Million)

TABLE 637.    Finland biosimilars market size, by manufacturer, 2017-2021 (USD Million)

TABLE 638.    Finland biosimilars market size, by manufacturer, 2022-2030 (USD Million)

TABLE 639.    Finland biosimilars market size, by technology, 2017-2021 (USD Million)

TABLE 640.    Finland biosimilars market size, by technology, 2022-2030 (USD Million)

TABLE 641.    Greece biosimilars market size, by product, 2017-2021 (USD Million)

TABLE 642.    Greece biosimilars market size, by product, 2022-2030 (USD Million)

TABLE 643.    Greece biosimilars market size, by recombinant non-glycosylated proteins, 2017-2021 (USD Million)

TABLE 644.    Greece biosimilars market size, by recombinant non-glycosylated proteins, 2022-2030 (USD Million)

TABLE 645.    Greece biosimilars market size, by interferon, 2017-2021 (USD Million)

TABLE 646.    Greece biosimilars market size, by interferon, 2022-2030 (USD Million)

TABLE 647.    Greece biosimilars market size, by recombinant glycosylated proteins, 2017-2021 (USD Million)

TABLE 648.    Greece biosimilars market size, by recombinant glycosylated proteins, 2022-2030 (USD Million)

TABLE 649.    Greece biosimilars market size, by erythropoietin, 2017-2021 (USD Million)

TABLE 650.    Greece biosimilars market size, by erythropoietin, 2022-2030 (USD Million)

TABLE 651.    Greece biosimilars market size, by monoclonal antibodies, 2017-2021 (USD Million)

TABLE 652.    Greece biosimilars market size, by monoclonal antibodies, 2022-2030 (USD Million)

TABLE 653.    Greece biosimilars market size, by follitropin, 2017-2021 (USD Million)

TABLE 654.    Greece biosimilars market size, by follitropin, 2022-2030 (USD Million)

TABLE 655.    Greece biosimilars market size, by application, 2017-2021 (USD Million)

TABLE 656.    Greece biosimilars market size, by application, 2022-2030 (USD Million)

TABLE 657.    Greece biosimilars market size, by hematology, 2017-2021 (USD Million)

TABLE 658.    Greece biosimilars market size, by hematology, 2022-2030 (USD Million)

TABLE 659.    Greece biosimilars market size, by oncology, 2017-2021 (USD Million)

TABLE 660.    Greece biosimilars market size, by oncology, 2022-2030 (USD Million)

TABLE 661.    Greece biosimilars market size, by leukemia, 2017-2021 (USD Million)

TABLE 662.    Greece biosimilars market size, by leukemia, 2022-2030 (USD Million)

TABLE 663.    Greece biosimilars market size, by autoimmune disease, 2017-2021 (USD Million)

TABLE 664.    Greece biosimilars market size, by autoimmune disease, 2022-2030 (USD Million)

TABLE 665.    Greece biosimilars market size, by arthritis, 2017-2021 (USD Million)

TABLE 666.    Greece biosimilars market size, by arthritis, 2022-2030 (USD Million)

TABLE 667.    Greece biosimilars market size, by inflammatory bowel disease, 2017-2021 (USD Million)

TABLE 668.    Greece biosimilars market size, by inflammatory bowel disease, 2022-2030 (USD Million)

TABLE 669.    Greece biosimilars market size, by manufacturer, 2017-2021 (USD Million)

TABLE 670.    Greece biosimilars market size, by manufacturer, 2022-2030 (USD Million)

TABLE 671.    Greece biosimilars market size, by technology, 2017-2021 (USD Million)

TABLE 672.    Greece biosimilars market size, by technology, 2022-2030 (USD Million)

TABLE 673.    Hungary biosimilars market size, by product, 2017-2021 (USD Million)

TABLE 674.    Hungary biosimilars market size, by product, 2022-2030 (USD Million)

TABLE 675.    Hungary biosimilars market size, by recombinant non-glycosylated proteins, 2017-2021 (USD Million)

TABLE 676.    Hungary biosimilars market size, by recombinant non-glycosylated proteins, 2022-2030 (USD Million)

TABLE 677.    Hungary biosimilars market size, by interferon, 2017-2021 (USD Million)

TABLE 678.    Hungary biosimilars market size, by interferon, 2022-2030 (USD Million)

TABLE 679.    Hungary biosimilars market size, by recombinant glycosylated proteins, 2017-2021 (USD Million)

TABLE 680.    Hungary biosimilars market size, by recombinant glycosylated proteins, 2022-2030 (USD Million)

TABLE 681.    Hungary biosimilars market size, by erythropoietin, 2017-2021 (USD Million)

TABLE 682.    Hungary biosimilars market size, by erythropoietin, 2022-2030 (USD Million)

TABLE 683.    Hungary biosimilars market size, by monoclonal antibodies, 2017-2021 (USD Million)

TABLE 684.    Hungary biosimilars market size, by monoclonal antibodies, 2022-2030 (USD Million)

TABLE 685.    Hungary biosimilars market size, by follitropin, 2017-2021 (USD Million)

TABLE 686.    Hungary biosimilars market size, by follitropin, 2022-2030 (USD Million)

TABLE 687.    Hungary biosimilars market size, by application, 2017-2021 (USD Million)

TABLE 688.    Hungary biosimilars market size, by application, 2022-2030 (USD Million)

TABLE 689.    Hungary biosimilars market size, by hematology, 2017-2021 (USD Million)

TABLE 690.    Hungary biosimilars market size, by hematology, 2022-2030 (USD Million)

TABLE 691.    Hungary biosimilars market size, by oncology, 2017-2021 (USD Million)

TABLE 692.    Hungary biosimilars market size, by oncology, 2022-2030 (USD Million)

TABLE 693.    Hungary biosimilars market size, by leukemia, 2017-2021 (USD Million)

TABLE 694.    Hungary biosimilars market size, by leukemia, 2022-2030 (USD Million)

TABLE 695.    Hungary biosimilars market size, by autoimmune disease, 2017-2021 (USD Million)

TABLE 696.    Hungary biosimilars market size, by autoimmune disease, 2022-2030 (USD Million)

TABLE 697.    Hungary biosimilars market size, by arthritis, 2017-2021 (USD Million)

TABLE 698.    Hungary biosimilars market size, by arthritis, 2022-2030 (USD Million)

TABLE 699.    Hungary biosimilars market size, by inflammatory bowel disease, 2017-2021 (USD Million)

TABLE 700.    Hungary biosimilars market size, by inflammatory bowel disease, 2022-2030 (USD Million)

TABLE 701.    Hungary biosimilars market size, by manufacturer, 2017-2021 (USD Million)

TABLE 702.    Hungary biosimilars market size, by manufacturer, 2022-2030 (USD Million)

TABLE 703.    Hungary biosimilars market size, by technology, 2017-2021 (USD Million)

TABLE 704.    Hungary biosimilars market size, by technology, 2022-2030 (USD Million)

TABLE 705.    Ireland biosimilars market size, by product, 2017-2021 (USD Million)

TABLE 706.    Ireland biosimilars market size, by product, 2022-2030 (USD Million)

TABLE 707.    Ireland biosimilars market size, by recombinant non-glycosylated proteins, 2017-2021 (USD Million)

TABLE 708.    Ireland biosimilars market size, by recombinant non-glycosylated proteins, 2022-2030 (USD Million)

TABLE 709.    Ireland biosimilars market size, by interferon, 2017-2021 (USD Million)

TABLE 710.    Ireland biosimilars market size, by interferon, 2022-2030 (USD Million)

TABLE 711.    Ireland biosimilars market size, by recombinant glycosylated proteins, 2017-2021 (USD Million)

TABLE 712.    Ireland biosimilars market size, by recombinant glycosylated proteins, 2022-2030 (USD Million)

TABLE 713.    Ireland biosimilars market size, by erythropoietin, 2017-2021 (USD Million)

TABLE 714.    Ireland biosimilars market size, by erythropoietin, 2022-2030 (USD Million)

TABLE 715.    Ireland biosimilars market size, by monoclonal antibodies, 2017-2021 (USD Million)

TABLE 716.    Ireland biosimilars market size, by monoclonal antibodies, 2022-2030 (USD Million)

TABLE 717.    Ireland biosimilars market size, by follitropin, 2017-2021 (USD Million)

TABLE 718.    Ireland biosimilars market size, by follitropin, 2022-2030 (USD Million)

TABLE 719.    Ireland biosimilars market size, by application, 2017-2021 (USD Million)

TABLE 720.    Ireland biosimilars market size, by application, 2022-2030 (USD Million)

TABLE 721.    Ireland biosimilars market size, by hematology, 2017-2021 (USD Million)

TABLE 722.    Ireland biosimilars market size, by hematology, 2022-2030 (USD Million)

TABLE 723.    Ireland biosimilars market size, by oncology, 2017-2021 (USD Million)

TABLE 724.    Ireland biosimilars market size, by oncology, 2022-2030 (USD Million)

TABLE 725.    Ireland biosimilars market size, by leukemia, 2017-2021 (USD Million)

TABLE 726.    Ireland biosimilars market size, by leukemia, 2022-2030 (USD Million)

TABLE 727.    Ireland biosimilars market size, by autoimmune disease, 2017-2021 (USD Million)

TABLE 728.    Ireland biosimilars market size, by autoimmune disease, 2022-2030 (USD Million)

TABLE 729.    Ireland biosimilars market size, by arthritis, 2017-2021 (USD Million)

TABLE 730.    Ireland biosimilars market size, by arthritis, 2022-2030 (USD Million)

TABLE 731.    Ireland biosimilars market size, by inflammatory bowel disease, 2017-2021 (USD Million)

TABLE 732.    Ireland biosimilars market size, by inflammatory bowel disease, 2022-2030 (USD Million)

TABLE 733.    Ireland biosimilars market size, by manufacturer, 2017-2021 (USD Million)

TABLE 734.    Ireland biosimilars market size, by manufacturer, 2022-2030 (USD Million)

TABLE 735.    Ireland biosimilars market size, by technology, 2017-2021 (USD Million)

TABLE 736.    Ireland biosimilars market size, by technology, 2022-2030 (USD Million)

TABLE 737.    Netherlands biosimilars market size, by product, 2017-2021 (USD Million)

TABLE 738.    Netherlands biosimilars market size, by product, 2022-2030 (USD Million)

TABLE 739.    Netherlands biosimilars market size, by recombinant non-glycosylated proteins, 2017-2021 (USD Million)

TABLE 740.    Netherlands biosimilars market size, by recombinant non-glycosylated proteins, 2022-2030 (USD Million)

TABLE 741.    Netherlands biosimilars market size, by interferon, 2017-2021 (USD Million)

TABLE 742.    Netherlands biosimilars market size, by interferon, 2022-2030 (USD Million)

TABLE 743.    Netherlands biosimilars market size, by recombinant glycosylated proteins, 2017-2021 (USD Million)

TABLE 744.    Netherlands biosimilars market size, by recombinant glycosylated proteins, 2022-2030 (USD Million)

TABLE 745.    Netherlands biosimilars market size, by erythropoietin, 2017-2021 (USD Million)

TABLE 746.    Netherlands biosimilars market size, by erythropoietin, 2022-2030 (USD Million)

TABLE 747.    Netherlands biosimilars market size, by monoclonal antibodies, 2017-2021 (USD Million)

TABLE 748.    Netherlands biosimilars market size, by monoclonal antibodies, 2022-2030 (USD Million)

TABLE 749.    Netherlands biosimilars market size, by follitropin, 2017-2021 (USD Million)

TABLE 750.    Netherlands biosimilars market size, by follitropin, 2022-2030 (USD Million)

TABLE 751.    Netherlands biosimilars market size, by application, 2017-2021 (USD Million)

TABLE 752.    Netherlands biosimilars market size, by application, 2022-2030 (USD Million)

TABLE 753.    Netherlands biosimilars market size, by hematology, 2017-2021 (USD Million)

TABLE 754.    Netherlands biosimilars market size, by hematology, 2022-2030 (USD Million)

TABLE 755.    Netherlands biosimilars market size, by oncology, 2017-2021 (USD Million)

TABLE 756.    Netherlands biosimilars market size, by oncology, 2022-2030 (USD Million)

TABLE 757.    Netherlands biosimilars market size, by leukemia, 2017-2021 (USD Million)

TABLE 758.    Netherlands biosimilars market size, by leukemia, 2022-2030 (USD Million)

TABLE 759.    Netherlands biosimilars market size, by autoimmune disease, 2017-2021 (USD Million)

TABLE 760.    Netherlands biosimilars market size, by autoimmune disease, 2022-2030 (USD Million)

TABLE 761.    Netherlands biosimilars market size, by arthritis, 2017-2021 (USD Million)

TABLE 762.    Netherlands biosimilars market size, by arthritis, 2022-2030 (USD Million)

TABLE 763.    Netherlands biosimilars market size, by inflammatory bowel disease, 2017-2021 (USD Million)

TABLE 764.    Netherlands biosimilars market size, by inflammatory bowel disease, 2022-2030 (USD Million)

TABLE 765.    Netherlands biosimilars market size, by manufacturer, 2017-2021 (USD Million)

TABLE 766.    Netherlands biosimilars market size, by manufacturer, 2022-2030 (USD Million)

TABLE 767.    Netherlands biosimilars market size, by technology, 2017-2021 (USD Million)

TABLE 768.    Netherlands biosimilars market size, by technology, 2022-2030 (USD Million)

TABLE 769.    Norway biosimilars market size, by product, 2017-2021 (USD Million)

TABLE 770.    Norway biosimilars market size, by product, 2022-2030 (USD Million)

TABLE 771.    Norway biosimilars market size, by recombinant non-glycosylated proteins, 2017-2021 (USD Million)

TABLE 772.    Norway biosimilars market size, by recombinant non-glycosylated proteins, 2022-2030 (USD Million)

TABLE 773.    Norway biosimilars market size, by interferon, 2017-2021 (USD Million)

TABLE 774.    Norway biosimilars market size, by interferon, 2022-2030 (USD Million)

TABLE 775.    Norway biosimilars market size, by recombinant glycosylated proteins, 2017-2021 (USD Million)

TABLE 776.    Norway biosimilars market size, by recombinant glycosylated proteins, 2022-2030 (USD Million)

TABLE 777.    Norway biosimilars market size, by erythropoietin, 2017-2021 (USD Million)

TABLE 778.    Norway biosimilars market size, by erythropoietin, 2022-2030 (USD Million)

TABLE 779.    Norway biosimilars market size, by monoclonal antibodies, 2017-2021 (USD Million)

TABLE 780.    Norway biosimilars market size, by monoclonal antibodies, 2022-2030 (USD Million)

TABLE 781.    Norway biosimilars market size, by follitropin, 2017-2021 (USD Million)

TABLE 782.    Norway biosimilars market size, by follitropin, 2022-2030 (USD Million)

TABLE 783.    Norway biosimilars market size, by application, 2017-2021 (USD Million)

TABLE 784.    Norway biosimilars market size, by application, 2022-2030 (USD Million)

TABLE 785.    Norway biosimilars market size, by hematology, 2017-2021 (USD Million)

TABLE 786.    Norway biosimilars market size, by hematology, 2022-2030 (USD Million)

TABLE 787.    Norway biosimilars market size, by oncology, 2017-2021 (USD Million)

TABLE 788.    Norway biosimilars market size, by oncology, 2022-2030 (USD Million)

TABLE 789.    Norway biosimilars market size, by leukemia, 2017-2021 (USD Million)

TABLE 790.    Norway biosimilars market size, by leukemia, 2022-2030 (USD Million)

TABLE 791.    Norway biosimilars market size, by autoimmune disease, 2017-2021 (USD Million)

TABLE 792.    Norway biosimilars market size, by autoimmune disease, 2022-2030 (USD Million)

TABLE 793.    Norway biosimilars market size, by arthritis, 2017-2021 (USD Million)

TABLE 794.    Norway biosimilars market size, by arthritis, 2022-2030 (USD Million)

TABLE 795.    Norway biosimilars market size, by inflammatory bowel disease, 2017-2021 (USD Million)

TABLE 796.    Norway biosimilars market size, by inflammatory bowel disease, 2022-2030 (USD Million)

TABLE 797.    Norway biosimilars market size, by manufacturer, 2017-2021 (USD Million)

TABLE 798.    Norway biosimilars market size, by manufacturer, 2022-2030 (USD Million)

TABLE 799.    Norway biosimilars market size, by technology, 2017-2021 (USD Million)

TABLE 800.    Norway biosimilars market size, by technology, 2022-2030 (USD Million)

TABLE 801.    Romania biosimilars market size, by product, 2017-2021 (USD Million)

TABLE 802.    Romania biosimilars market size, by product, 2022-2030 (USD Million)

TABLE 803.    Romania biosimilars market size, by recombinant non-glycosylated proteins, 2017-2021 (USD Million)

TABLE 804.    Romania biosimilars market size, by recombinant non-glycosylated proteins, 2022-2030 (USD Million)

TABLE 805.    Romania biosimilars market size, by interferon, 2017-2021 (USD Million)

TABLE 806.    Romania biosimilars market size, by interferon, 2022-2030 (USD Million)

TABLE 807.    Romania biosimilars market size, by recombinant glycosylated proteins, 2017-2021 (USD Million)

TABLE 808.    Romania biosimilars market size, by recombinant glycosylated proteins, 2022-2030 (USD Million)

TABLE 809.    Romania biosimilars market size, by erythropoietin, 2017-2021 (USD Million)

TABLE 810.    Romania biosimilars market size, by erythropoietin, 2022-2030 (USD Million)

TABLE 811.    Romania biosimilars market size, by monoclonal antibodies, 2017-2021 (USD Million)

TABLE 812.    Romania biosimilars market size, by monoclonal antibodies, 2022-2030 (USD Million)

TABLE 813.    Romania biosimilars market size, by follitropin, 2017-2021 (USD Million)

TABLE 814.    Romania biosimilars market size, by follitropin, 2022-2030 (USD Million)

TABLE 815.    Romania biosimilars market size, by application, 2017-2021 (USD Million)

TABLE 816.    Romania biosimilars market size, by application, 2022-2030 (USD Million)

TABLE 817.    Romania biosimilars market size, by hematology, 2017-2021 (USD Million)

TABLE 818.    Romania biosimilars market size, by hematology, 2022-2030 (USD Million)

TABLE 819.    Romania biosimilars market size, by oncology, 2017-2021 (USD Million)

TABLE 820.    Romania biosimilars market size, by oncology, 2022-2030 (USD Million)

TABLE 821.    Romania biosimilars market size, by leukemia, 2017-2021 (USD Million)

TABLE 822.    Romania biosimilars market size, by leukemia, 2022-2030 (USD Million)

TABLE 823.    Romania biosimilars market size, by autoimmune disease, 2017-2021 (USD Million)

TABLE 824.    Romania biosimilars market size, by autoimmune disease, 2022-2030 (USD Million)

TABLE 825.    Romania biosimilars market size, by arthritis, 2017-2021 (USD Million)

TABLE 826.    Romania biosimilars market size, by arthritis, 2022-2030 (USD Million)

TABLE 827.    Romania biosimilars market size, by inflammatory bowel disease, 2017-2021 (USD Million)

TABLE 828.    Romania biosimilars market size, by inflammatory bowel disease, 2022-2030 (USD Million)

TABLE 829.    Romania biosimilars market size, by manufacturer, 2017-2021 (USD Million)

TABLE 830.    Romania biosimilars market size, by manufacturer, 2022-2030 (USD Million)

TABLE 831.    Romania biosimilars market size, by technology, 2017-2021 (USD Million)

TABLE 832.    Romania biosimilars market size, by technology, 2022-2030 (USD Million)

TABLE 833.    Slovakia biosimilars market size, by product, 2017-2021 (USD Million)

TABLE 834.    Slovakia biosimilars market size, by product, 2022-2030 (USD Million)

TABLE 835.    Slovakia biosimilars market size, by recombinant non-glycosylated proteins, 2017-2021 (USD Million)

TABLE 836.    Slovakia biosimilars market size, by recombinant non-glycosylated proteins, 2022-2030 (USD Million)

TABLE 837.    Slovakia biosimilars market size, by interferon, 2017-2021 (USD Million)

TABLE 838.    Slovakia biosimilars market size, by interferon, 2022-2030 (USD Million)

TABLE 839.    Slovakia biosimilars market size, by recombinant glycosylated proteins, 2017-2021 (USD Million)

TABLE 840.    Slovakia biosimilars market size, by recombinant glycosylated proteins, 2022-2030 (USD Million)

TABLE 841.    Slovakia biosimilars market size, by erythropoietin, 2017-2021 (USD Million)

TABLE 842.    Slovakia biosimilars market size, by erythropoietin, 2022-2030 (USD Million)

TABLE 843.    Slovakia biosimilars market size, by monoclonal antibodies, 2017-2021 (USD Million)

TABLE 844.    Slovakia biosimilars market size, by monoclonal antibodies, 2022-2030 (USD Million)

TABLE 845.    Slovakia biosimilars market size, by follitropin, 2017-2021 (USD Million)

TABLE 846.    Slovakia biosimilars market size, by follitropin, 2022-2030 (USD Million)

TABLE 847.    Slovakia biosimilars market size, by application, 2017-2021 (USD Million)

TABLE 848.    Slovakia biosimilars market size, by application, 2022-2030 (USD Million)

TABLE 849.    Slovakia biosimilars market size, by hematology, 2017-2021 (USD Million)

TABLE 850.    Slovakia biosimilars market size, by hematology, 2022-2030 (USD Million)

TABLE 851.    Slovakia biosimilars market size, by oncology, 2017-2021 (USD Million)

TABLE 852.    Slovakia biosimilars market size, by oncology, 2022-2030 (USD Million)

TABLE 853.    Slovakia biosimilars market size, by leukemia, 2017-2021 (USD Million)

TABLE 854.    Slovakia biosimilars market size, by leukemia, 2022-2030 (USD Million)

TABLE 855.    Slovakia biosimilars market size, by autoimmune disease, 2017-2021 (USD Million)

TABLE 856.    Slovakia biosimilars market size, by autoimmune disease, 2022-2030 (USD Million)

TABLE 857.    Slovakia biosimilars market size, by arthritis, 2017-2021 (USD Million)

TABLE 858.    Slovakia biosimilars market size, by arthritis, 2022-2030 (USD Million)

TABLE 859.    Slovakia biosimilars market size, by inflammatory bowel disease, 2017-2021 (USD Million)

TABLE 860.    Slovakia biosimilars market size, by inflammatory bowel disease, 2022-2030 (USD Million)

TABLE 861.    Slovakia biosimilars market size, by manufacturer, 2017-2021 (USD Million)

TABLE 862.    Slovakia biosimilars market size, by manufacturer, 2022-2030 (USD Million)

TABLE 863.    Slovakia biosimilars market size, by technology, 2017-2021 (USD Million)

TABLE 864.    Slovakia biosimilars market size, by technology, 2022-2030 (USD Million)

TABLE 865.    Slovenia biosimilars market size, by product, 2017-2021 (USD Million)

TABLE 866.    Slovenia biosimilars market size, by product, 2022-2030 (USD Million)

TABLE 867.    Slovenia biosimilars market size, by recombinant non-glycosylated proteins, 2017-2021 (USD Million)

TABLE 868.    Slovenia biosimilars market size, by recombinant non-glycosylated proteins, 2022-2030 (USD Million)

TABLE 869.    Slovenia biosimilars market size, by interferon, 2017-2021 (USD Million)

TABLE 870.    Slovenia biosimilars market size, by interferon, 2022-2030 (USD Million)

TABLE 871.    Slovenia biosimilars market size, by recombinant glycosylated proteins, 2017-2021 (USD Million)

TABLE 872.    Slovenia biosimilars market size, by recombinant glycosylated proteins, 2022-2030 (USD Million)

TABLE 873.    Slovenia biosimilars market size, by erythropoietin, 2017-2021 (USD Million)

TABLE 874.    Slovenia biosimilars market size, by erythropoietin, 2022-2030 (USD Million)

TABLE 875.    Slovenia biosimilars market size, by monoclonal antibodies, 2017-2021 (USD Million)

TABLE 876.    Slovenia biosimilars market size, by monoclonal antibodies, 2022-2030 (USD Million)

TABLE 877.    Slovenia biosimilars market size, by follitropin, 2017-2021 (USD Million)

TABLE 878.    Slovenia biosimilars market size, by follitropin, 2022-2030 (USD Million)

TABLE 879.    Slovenia biosimilars market size, by application, 2017-2021 (USD Million)

TABLE 880.    Slovenia biosimilars market size, by application, 2022-2030 (USD Million)

TABLE 881.    Slovenia biosimilars market size, by hematology, 2017-2021 (USD Million)

TABLE 882.    Slovenia biosimilars market size, by hematology, 2022-2030 (USD Million)

TABLE 883.    Slovenia biosimilars market size, by oncology, 2017-2021 (USD Million)

TABLE 884.    Slovenia biosimilars market size, by oncology, 2022-2030 (USD Million)

TABLE 885.    Slovenia biosimilars market size, by leukemia, 2017-2021 (USD Million)

TABLE 886.    Slovenia biosimilars market size, by leukemia, 2022-2030 (USD Million)

TABLE 887.    Slovenia biosimilars market size, by autoimmune disease, 2017-2021 (USD Million)

TABLE 888.    Slovenia biosimilars market size, by autoimmune disease, 2022-2030 (USD Million)

TABLE 889.    Slovenia biosimilars market size, by arthritis, 2017-2021 (USD Million)

TABLE 890.    Slovenia biosimilars market size, by arthritis, 2022-2030 (USD Million)

TABLE 891.    Slovenia biosimilars market size, by inflammatory bowel disease, 2017-2021 (USD Million)

TABLE 892.    Slovenia biosimilars market size, by inflammatory bowel disease, 2022-2030 (USD Million)

TABLE 893.    Slovenia biosimilars market size, by manufacturer, 2017-2021 (USD Million)

TABLE 894.    Slovenia biosimilars market size, by manufacturer, 2022-2030 (USD Million)

TABLE 895.    Slovenia biosimilars market size, by technology, 2017-2021 (USD Million)

TABLE 896.    Slovenia biosimilars market size, by technology, 2022-2030 (USD Million)

TABLE 897.    Sweden biosimilars market size, by product, 2017-2021 (USD Million)

TABLE 898.    Sweden biosimilars market size, by product, 2022-2030 (USD Million)

TABLE 899.    Sweden biosimilars market size, by recombinant non-glycosylated proteins, 2017-2021 (USD Million)

TABLE 900.    Sweden biosimilars market size, by recombinant non-glycosylated proteins, 2022-2030 (USD Million)

TABLE 901.    Sweden biosimilars market size, by interferon, 2017-2021 (USD Million)

TABLE 902.    Sweden biosimilars market size, by interferon, 2022-2030 (USD Million)

TABLE 903.    Sweden biosimilars market size, by recombinant glycosylated proteins, 2017-2021 (USD Million)

TABLE 904.    Sweden biosimilars market size, by recombinant glycosylated proteins, 2022-2030 (USD Million)

TABLE 905.    Sweden biosimilars market size, by erythropoietin, 2017-2021 (USD Million)

TABLE 906.    Sweden biosimilars market size, by erythropoietin, 2022-2030 (USD Million)

TABLE 907.    Sweden biosimilars market size, by monoclonal antibodies, 2017-2021 (USD Million)

TABLE 908.    Sweden biosimilars market size, by monoclonal antibodies, 2022-2030 (USD Million)

TABLE 909.    Sweden biosimilars market size, by follitropin, 2017-2021 (USD Million)

TABLE 910.    Sweden biosimilars market size, by follitropin, 2022-2030 (USD Million)

TABLE 911.    Sweden biosimilars market size, by application, 2017-2021 (USD Million)

TABLE 912.    Sweden biosimilars market size, by application, 2022-2030 (USD Million)

TABLE 913.    Sweden biosimilars market size, by hematology, 2017-2021 (USD Million)

TABLE 914.    Sweden biosimilars market size, by hematology, 2022-2030 (USD Million)

TABLE 915.    Sweden biosimilars market size, by oncology, 2017-2021 (USD Million)

TABLE 916.    Sweden biosimilars market size, by oncology, 2022-2030 (USD Million)

TABLE 917.    Sweden biosimilars market size, by leukemia, 2017-2021 (USD Million)

TABLE 918.    Sweden biosimilars market size, by leukemia, 2022-2030 (USD Million)

TABLE 919.    Sweden biosimilars market size, by autoimmune disease, 2017-2021 (USD Million)

TABLE 920.    Sweden biosimilars market size, by autoimmune disease, 2022-2030 (USD Million)

TABLE 921.    Sweden biosimilars market size, by arthritis, 2017-2021 (USD Million)

TABLE 922.    Sweden biosimilars market size, by arthritis, 2022-2030 (USD Million)

TABLE 923.    Sweden biosimilars market size, by inflammatory bowel disease, 2017-2021 (USD Million)

TABLE 924.    Sweden biosimilars market size, by inflammatory bowel disease, 2022-2030 (USD Million)

TABLE 925.    Sweden biosimilars market size, by manufacturer, 2017-2021 (USD Million)

TABLE 926.    Sweden biosimilars market size, by manufacturer, 2022-2030 (USD Million)

TABLE 927.    Sweden biosimilars market size, by technology, 2017-2021 (USD Million)

TABLE 928.    Sweden biosimilars market size, by technology, 2022-2030 (USD Million)

TABLE 929.    Switzerland biosimilars market size, by product, 2017-2021 (USD Million)

TABLE 930.    Switzerland biosimilars market size, by product, 2022-2030 (USD Million)

TABLE 931.    Switzerland biosimilars market size, by recombinant non-glycosylated proteins, 2017-2021 (USD Million)

TABLE 932.    Switzerland biosimilars market size, by recombinant non-glycosylated proteins, 2022-2030 (USD Million)

TABLE 933.    Switzerland biosimilars market size, by interferon, 2017-2021 (USD Million)

TABLE 934.    Switzerland biosimilars market size, by interferon, 2022-2030 (USD Million)

TABLE 935.    Switzerland biosimilars market size, by recombinant glycosylated proteins, 2017-2021 (USD Million)

TABLE 936.    Switzerland biosimilars market size, by recombinant glycosylated proteins, 2022-2030 (USD Million)

TABLE 937.    Switzerland biosimilars market size, by erythropoietin, 2017-2021 (USD Million)

TABLE 938.    Switzerland biosimilars market size, by erythropoietin, 2022-2030 (USD Million)

TABLE 939.    Switzerland biosimilars market size, by monoclonal antibodies, 2017-2021 (USD Million)

TABLE 940.    Switzerland biosimilars market size, by monoclonal antibodies, 2022-2030 (USD Million)

TABLE 941.    Switzerland biosimilars market size, by follitropin, 2017-2021 (USD Million)

TABLE 942.    Switzerland biosimilars market size, by follitropin, 2022-2030 (USD Million)

TABLE 943.    Switzerland biosimilars market size, by application, 2017-2021 (USD Million)

TABLE 944.    Switzerland biosimilars market size, by application, 2022-2030 (USD Million)

TABLE 945.    Switzerland biosimilars market size, by hematology, 2017-2021 (USD Million)

TABLE 946.    Switzerland biosimilars market size, by hematology, 2022-2030 (USD Million)

TABLE 947.    Switzerland biosimilars market size, by oncology, 2017-2021 (USD Million)

TABLE 948.    Switzerland biosimilars market size, by oncology, 2022-2030 (USD Million)

TABLE 949.    Switzerland biosimilars market size, by leukemia, 2017-2021 (USD Million)

TABLE 950.    Switzerland biosimilars market size, by leukemia, 2022-2030 (USD Million)

TABLE 951.    Switzerland biosimilars market size, by autoimmune disease, 2017-2021 (USD Million)

TABLE 952.    Switzerland biosimilars market size, by autoimmune disease, 2022-2030 (USD Million)

TABLE 953.    Switzerland biosimilars market size, by arthritis, 2017-2021 (USD Million)

TABLE 954.    Switzerland biosimilars market size, by arthritis, 2022-2030 (USD Million)

TABLE 955.    Switzerland biosimilars market size, by inflammatory bowel disease, 2017-2021 (USD Million)

TABLE 956.    Switzerland biosimilars market size, by inflammatory bowel disease, 2022-2030 (USD Million)

TABLE 957.    Switzerland biosimilars market size, by manufacturer, 2017-2021 (USD Million)

TABLE 958.    Switzerland biosimilars market size, by manufacturer, 2022-2030 (USD Million)

TABLE 959.    Switzerland biosimilars market size, by technology, 2017-2021 (USD Million)

TABLE 960.    Switzerland biosimilars market size, by technology, 2022-2030 (USD Million)

TABLE 961.    Asia Pacific biosimilars market size, by country, 2017-2021 (USD Million)

TABLE 962.    Asia Pacific biosimilars market size, by country, 2022-2030 (USD Million)

TABLE 963.    Asia Pacific biosimilars market size, by product, 2017-2021 (USD Million)

TABLE 964.    Asia Pacific biosimilars market size, by product, 2022-2030 (USD Million)

TABLE 965.    Asia Pacific biosimilars market size, by recombinant non-glycosylated proteins, 2017-2021 (USD Million)

TABLE 966.    Asia Pacific biosimilars market size, by recombinant non-glycosylated proteins, 2022-2030 (USD Million)

TABLE 967.    Asia Pacific biosimilars market size, by interferon, 2017-2021 (USD Million)

TABLE 968.    Asia Pacific biosimilars market size, by interferon, 2022-2030 (USD Million)

TABLE 969.    Asia Pacific biosimilars market size, by recombinant glycosylated proteins, 2017-2021 (USD Million)

TABLE 970.    Asia Pacific biosimilars market size, by recombinant glycosylated proteins, 2022-2030 (USD Million)

TABLE 971.    Asia Pacific biosimilars market size, by erythropoietin, 2017-2021 (USD Million)

TABLE 972.    Asia Pacific biosimilars market size, by erythropoietin, 2022-2030 (USD Million)

TABLE 973.    Asia Pacific biosimilars market size, by monoclonal antibodies, 2017-2021 (USD Million)

TABLE 974.    Asia Pacific biosimilars market size, by monoclonal antibodies, 2022-2030 (USD Million)

TABLE 975.    Asia Pacific biosimilars market size, by follitropin, 2017-2021 (USD Million)

TABLE 976.    Asia Pacific biosimilars market size, by follitropin, 2022-2030 (USD Million)

TABLE 977.    Asia Pacific biosimilars market size, by application, 2017-2021 (USD Million)

TABLE 978.    Asia Pacific biosimilars market size, by application, 2022-2030 (USD Million)

TABLE 979.    Asia Pacific biosimilars market size, by hematology, 2017-2021 (USD Million)

TABLE 980.    Asia Pacific biosimilars market size, by hematology, 2022-2030 (USD Million)

TABLE 981.    Asia Pacific biosimilars market size, by oncology, 2017-2021 (USD Million)

TABLE 982.    Asia Pacific biosimilars market size, by oncology, 2022-2030 (USD Million)

TABLE 983.    Asia Pacific biosimilars market size, by leukemia, 2017-2021 (USD Million)

TABLE 984.    Asia Pacific biosimilars market size, by leukemia, 2022-2030 (USD Million)

TABLE 985.    Asia Pacific biosimilars market size, by autoimmune disease, 2017-2021 (USD Million)

TABLE 986.    Asia Pacific biosimilars market size, by autoimmune disease, 2022-2030 (USD Million)

TABLE 987.    Asia Pacific biosimilars market size, by arthritis, 2017-2021 (USD Million)

TABLE 988.    Asia Pacific biosimilars market size, by arthritis, 2022-2030 (USD Million)

TABLE 989.    Asia Pacific biosimilars market size, by inflammatory bowel disease, 2017-2021 (USD Million)

TABLE 990.    Asia Pacific biosimilars market size, by inflammatory bowel disease, 2022-2030 (USD Million)

TABLE 991.    Asia Pacific biosimilars market size, by manufacturer, 2017-2021 (USD Million)

TABLE 992.    Asia Pacific biosimilars market size, by manufacturer, 2022-2030 (USD Million)

TABLE 993.    Asia Pacific biosimilars market size, by technology, 2017-2021 (USD Million)

TABLE 994.    Asia Pacific biosimilars market size, by technology, 2022-2030 (USD Million)

TABLE 995.    China biosimilars market size, by product, 2017-2021 (USD Million)

TABLE 996.    China biosimilars market size, by product, 2022-2030 (USD Million)

TABLE 997.    China biosimilars market size, by recombinant non-glycosylated proteins, 2017-2021 (USD Million)

TABLE 998.    China biosimilars market size, by recombinant non-glycosylated proteins, 2022-2030 (USD Million)

TABLE 999.    China biosimilars market size, by interferon, 2017-2021 (USD Million)

TABLE 1000.    China biosimilars market size, by interferon, 2022-2030 (USD Million)

TABLE 1001.    China biosimilars market size, by recombinant glycosylated proteins, 2017-2021 (USD Million)

TABLE 1002.    China biosimilars market size, by recombinant glycosylated proteins, 2022-2030 (USD Million)

TABLE 1003.    China biosimilars market size, by erythropoietin, 2017-2021 (USD Million)

TABLE 1004.    China biosimilars market size, by erythropoietin, 2022-2030 (USD Million)

TABLE 1005.    China biosimilars market size, by monoclonal antibodies, 2017-2021 (USD Million)

TABLE 1006.    China biosimilars market size, by monoclonal antibodies, 2022-2030 (USD Million)

TABLE 1007.    China biosimilars market size, by Follitropin, 2017-2021 (USD Million)

TABLE 1008.    China biosimilars market size, by Follitropin, 2022-2030 (USD Million)

TABLE 1009.    China biosimilars market size, by application, 2017-2021 (USD Million)

TABLE 1010.    China biosimilars market size, by application, 2022-2030 (USD Million)

TABLE 1011.    China biosimilars market size, by hematology, 2017-2021 (USD Million)

TABLE 1012.    China biosimilars market size, by hematology, 2022-2030 (USD Million)

TABLE 1013.    China biosimilars market size, by oncology, 2017-2021 (USD Million)

TABLE 1014.    China biosimilars market size, by oncology, 2022-2030 (USD Million)

TABLE 1015.    China biosimilars market size, by leukemia, 2017-2021 (USD Million)

TABLE 1016.    China biosimilars market size, by leukemia, 2022-2030 (USD Million)

TABLE 1017.    China biosimilars market size, by autoimmune disease, 2017-2021 (USD Million)

TABLE 1018.    China biosimilars market size, by autoimmune disease, 2022-2030 (USD Million)

TABLE 1019.    China biosimilars market size, by arthritis, 2017-2021 (USD Million)

TABLE 1020.    China biosimilars market size, by arthritis, 2022-2030 (USD Million)

TABLE 1021.    China biosimilars market size, by inflammatory bowel disease, 2017-2021 (USD Million)

TABLE 1022.    China biosimilars market size, by inflammatory bowel disease, 2022-2030 (USD Million)

TABLE 1023.    China biosimilars market size, by manufacturer, 2017-2021 (USD Million)

TABLE 1024.    China biosimilars market size, by manufacturer, 2022-2030 (USD Million)

TABLE 1025.    China biosimilars market size, by technology, 2017-2021 (USD Million)

TABLE 1026.    China biosimilars market size, by technology, 2022-2030 (USD Million)

TABLE 1027.    Japan biosimilars market size, by product, 2017-2021 (USD Million)

TABLE 1028.    Japan biosimilars market size, by product, 2022-2030 (USD Million)

TABLE 1029.    Japan biosimilars market size, by recombinant non-glycosylated proteins, 2017-2021 (USD Million)

TABLE 1030.    Japan biosimilars market size, by recombinant non-glycosylated proteins, 2022-2030 (USD Million)

TABLE 1031.    Japan biosimilars market size, by recombinant glycosylated proteins, 2017-2021 (USD Million)

TABLE 1032.    Japan biosimilars market size, by recombinant glycosylated proteins, 2022-2030 (USD Million)

TABLE 1033.    Japan biosimilars market size, by erythropoietin, 2017-2021 (USD Million)

TABLE 1034.    Japan biosimilars market size, by erythropoietin, 2022-2030 (USD Million)

TABLE 1035.    Japan biosimilars market size, by monoclonal antibodies, 2017-2021 (USD Million)

TABLE 1036.    Japan biosimilars market size, by monoclonal antibodies, 2022-2030 (USD Million)

TABLE 1037.    Japan biosimilars market size, by application, 2017-2021 (USD Million)

TABLE 1038.    Japan biosimilars market size, by application, 2022-2030 (USD Million)

TABLE 1039.    Japan biosimilars market size, by hematology, 2017-2021 (USD Million)

TABLE 1040.    Japan biosimilars market size, by hematology, 2022-2030 (USD Million)

TABLE 1041.    Japan biosimilars market size, by oncology, 2017-2021 (USD Million)

TABLE 1042.    Japan biosimilars market size, by oncology, 2022-2030 (USD Million)

TABLE 1043.    Japan biosimilars market size, by leukemia, 2017-2021 (USD Million)

TABLE 1044.    Japan biosimilars market size, by leukemia, 2022-2030 (USD Million)

TABLE 1045.    Japan biosimilars market size, by autoimmune disease, 2017-2021 (USD Million)

TABLE 1046.    Japan biosimilars market size, by autoimmune disease, 2022-2030 (USD Million)

TABLE 1047.    Japan biosimilars market size, by arthritis, 2017-2021 (USD Million)

TABLE 1048.    Japan biosimilars market size, by arthritis, 2022-2030 (USD Million)

TABLE 1049.    Japan biosimilars market size, by inflammatory bowel disease, 2017-2021 (USD Million)

TABLE 1050.    Japan biosimilars market size, by inflammatory bowel disease, 2022-2030 (USD Million)

TABLE 1051.    Japan biosimilars market size, by manufacturer, 2017-2021 (USD Million)

TABLE 1052.    Japan biosimilars market size, by manufacturer, 2022-2030 (USD Million)

TABLE 1053.    Japan biosimilars market size, by technology, 2017-2021 (USD Million)

TABLE 1054.    Japan biosimilars market size, by technology, 2022-2030 (USD Million)

TABLE 1055.    India biosimilars market size, by product, 2017-2021 (USD Million)

TABLE 1056.    India biosimilars market size, by product, 2022-2030 (USD Million)

TABLE 1057.    India biosimilars market size, by recombinant non-glycosylated proteins, 2017-2021 (USD Million)

TABLE 1058.    India biosimilars market size, by recombinant non-glycosylated proteins, 2022-2030 (USD Million)

TABLE 1059.    India biosimilars market size, by interferon, 2017-2021 (USD Million)

TABLE 1060.    India biosimilars market size, by interferon, 2022-2030 (USD Million)

TABLE 1061.    India biosimilars market size, by recombinant glycosylated proteins, 2017-2021 (USD Million)

TABLE 1062.    India biosimilars market size, by recombinant glycosylated proteins, 2022-2030 (USD Million)

TABLE 1063.    India biosimilars market size, by erythropoietin, 2017-2021 (USD Million)

TABLE 1064.    India biosimilars market size, by erythropoietin, 2022-2030 (USD Million)

TABLE 1065.    India biosimilars market size, by monoclonal antibodies, 2017-2021 (USD Million)

TABLE 1066.    India biosimilars market size, by monoclonal antibodies, 2022-2030 (USD Million)

TABLE 1067.    India biosimilars market size, by Follitropin, 2017-2021 (USD Million)

TABLE 1068.    India biosimilars market size, by Follitropin, 2022-2030 (USD Million)

TABLE 1069.    India biosimilars market size, by application, 2017-2021 (USD Million)

TABLE 1070.    India biosimilars market size, by application, 2022-2030 (USD Million)

TABLE 1071.    India biosimilars market size, by hematology, 2017-2021 (USD Million)

TABLE 1072.    India biosimilars market size, by hematology, 2022-2030 (USD Million)

TABLE 1073.    India biosimilars market size, by oncology, 2017-2021 (USD Million)

TABLE 1074.    India biosimilars market size, by oncology, 2022-2030 (USD Million)

TABLE 1075.    India biosimilars market size, by leukemia, 2017-2021 (USD Million)

TABLE 1076.    India biosimilars market size, by leukemia, 2022-2030 (USD Million)

TABLE 1077.    India biosimilars market size, by autoimmune disease, 2017-2021 (USD Million)

TABLE 1078.    India biosimilars market size, by autoimmune disease, 2022-2030 (USD Million)

TABLE 1079.    India biosimilars market size, by arthritis, 2017-2021 (USD Million)

TABLE 1080.    India biosimilars market size, by arthritis, 2022-2030 (USD Million)

TABLE 1081.    India biosimilars market size, by inflammatory bowel disease, 2017-2021 (USD Million)

TABLE 1082.    India biosimilars market size, by inflammatory bowel disease, 2022-2030 (USD Million)

TABLE 1083.    India biosimilars market size, by manufacturer, 2017-2021 (USD Million)

TABLE 1084.    India biosimilars market size, by manufacturer, 2022-2030 (USD Million)

TABLE 1085.    India biosimilars market size, by technology, 2017-2021 (USD Million)

TABLE 1086.    India biosimilars market size, by technology, 2022-2030 (USD Million)

TABLE 1087.    South Korea biosimilars market size, by product, 2017-2021 (USD Million)

TABLE 1088.    South Korea biosimilars market size, by product, 2022-2030 (USD Million)

TABLE 1089.    South Korea biosimilars market size, by recombinant non-glycosylated proteins, 2017-2021 (USD Million)

TABLE 1090.    South Korea biosimilars market size, by recombinant non-glycosylated proteins, 2022-2030 (USD Million)

TABLE 1091.    South Korea biosimilars market size, by recombinant glycosylated proteins, 2017-2021 (USD Million)

TABLE 1092.    South Korea biosimilars market size, by recombinant glycosylated proteins, 2022-2030 (USD Million)

TABLE 1093.    South Korea biosimilars market size, by monoclonal antibodies, 2017-2021 (USD Million)

TABLE 1094.    South Korea biosimilars market size, by monoclonal antibodies, 2022-2030 (USD Million)

TABLE 1095.    South Korea biosimilars market size, by application, 2017-2021 (USD Million)

TABLE 1096.    South Korea biosimilars market size, by application, 2022-2030 (USD Million)

TABLE 1097.    South Korea biosimilars market size, by oncology, 2017-2021 (USD Million)

TABLE 1098.    South Korea biosimilars market size, by oncology, 2022-2030 (USD Million)

TABLE 1099.    South Korea biosimilars market size, by leukemia, 2017-2021 (USD Million)

TABLE 1100.    South Korea biosimilars market size, by leukemia, 2022-2030 (USD Million)

TABLE 1101.    South Korea biosimilars market size, by autoimmune disease, 2017-2021 (USD Million)

TABLE 1102.    South Korea biosimilars market size, by autoimmune disease, 2022-2030 (USD Million)

TABLE 1103.    South Korea biosimilars market size, by arthritis, 2017-2021 (USD Million)

TABLE 1104.    South Korea biosimilars market size, by arthritis, 2022-2030 (USD Million)

TABLE 1105.    South Korea biosimilars market size, by inflammatory bowel disease, 2017-2021 (USD Million)

TABLE 1106.    South Korea biosimilars market size, by inflammatory bowel disease, 2022-2030 (USD Million)

TABLE 1107.    South Korea biosimilars market size, by manufacturer, 2017-2021 (USD Million)

TABLE 1108.    South Korea biosimilars market size, by manufacturer, 2022-2030 (USD Million)

TABLE 1109.    South Korea biosimilars market size, by technology, 2017-2021 (USD Million)

TABLE 1110.    South Korea biosimilars market size, by technology, 2022-2030 (USD Million)

TABLE 1111.    Australia biosimilars market size, by product, 2017-2021 (USD Million)

TABLE 1112.    Australia biosimilars market size, by product, 2022-2030 (USD Million)

TABLE 1113.    Australia biosimilars market size, by recombinant non-glycosylated proteins, 2017-2021 (USD Million)

TABLE 1114.    Australia biosimilars market size, by recombinant non-glycosylated proteins, 2022-2030 (USD Million)

TABLE 1115.    Australia biosimilars market size, by recombinant glycosylated proteins, 2017-2021 (USD Million)

TABLE 1116.    Australia biosimilars market size, by recombinant glycosylated proteins, 2022-2030 (USD Million)

TABLE 1117.    Australia biosimilars market size, by erythropoietin, 2017-2021 (USD Million)

TABLE 1118.    Australia biosimilars market size, by erythropoietin, 2022-2030 (USD Million)

TABLE 1119.    Australia biosimilars market size, by monoclonal antibodies, 2017-2021 (USD Million)

TABLE 1120.    Australia biosimilars market size, by monoclonal antibodies, 2022-2030 (USD Million)

TABLE 1121.    Australia biosimilars market size, by Follitropin, 2017-2021 (USD Million)

TABLE 1122.    Australia biosimilars market size, by Follitropin, 2022-2030 (USD Million)

TABLE 1123.    Australia biosimilars market size, by application, 2017-2021 (USD Million)

TABLE 1124.    Australia biosimilars market size, by application, 2022-2030 (USD Million)

TABLE 1125.    Australia biosimilars market size, by hematology, 2017-2021 (USD Million)

TABLE 1126.    Australia biosimilars market size, by hematology, 2022-2030 (USD Million)

TABLE 1127.    Australia biosimilars market size, by oncology, 2017-2021 (USD Million)

TABLE 1128.    Australia biosimilars market size, by oncology, 2022-2030 (USD Million)

TABLE 1129.    Australia biosimilars market size, by leukemia, 2017-2021 (USD Million)

TABLE 1130.    Australia biosimilars market size, by leukemia, 2022-2030 (USD Million)

TABLE 1131.    Australia biosimilars market size, by autoimmune disease, 2017-2021 (USD Million)

TABLE 1132.    Australia biosimilars market size, by autoimmune disease, 2022-2030 (USD Million)

TABLE 1133.    Australia biosimilars market size, by arthritis, 2017-2021 (USD Million)

TABLE 1134.    Australia biosimilars market size, by arthritis, 2022-2030 (USD Million)

TABLE 1135.    Australia biosimilars market size, by inflammatory bowel disease, 2017-2021 (USD Million)

TABLE 1136.    Australia biosimilars market size, by inflammatory bowel disease, 2022-2030 (USD Million)

TABLE 1137.    Australia biosimilars market size, by manufacturer, 2017-2021 (USD Million)

TABLE 1138.    Australia biosimilars market size, by manufacturer, 2022-2030 (USD Million)

TABLE 1139.    Australia biosimilars market size, by technology, 2017-2021 (USD Million)

TABLE 1140.    Australia biosimilars market size, by technology, 2022-2030 (USD Million)

TABLE 1141.    New Zealand biosimilars market size, by product, 2017-2021 (USD Million)

TABLE 1142.    New Zealand biosimilars market size, by product, 2022-2030 (USD Million)

TABLE 1143.    New Zealand biosimilars market size, by recombinant non-glycosylated proteins, 2017-2021 (USD Million)

TABLE 1144.    New Zealand biosimilars market size, by recombinant non-glycosylated proteins, 2022-2030 (USD Million)

TABLE 1145.    New Zealand biosimilars market size, by recombinant glycosylated proteins, 2017-2021 (USD Million)

TABLE 1146.    New Zealand biosimilars market size, by recombinant glycosylated proteins, 2022-2030 (USD Million)

TABLE 1147.    New Zealand biosimilars market size, by erythropoietin, 2017-2021 (USD Million)

TABLE 1148.    New Zealand biosimilars market size, by erythropoietin, 2022-2030 (USD Million)

TABLE 1149.    New Zealand biosimilars market size, by application, 2017-2021 (USD Million)

TABLE 1150.    New Zealand biosimilars market size, by application, 2022-2030 (USD Million)

TABLE 1151.    New Zealand biosimilars market size, by hematology, 2017-2021 (USD Million)

TABLE 1152.    New Zealand biosimilars market size, by hematology, 2022-2030 (USD Million)

TABLE 1153.    New Zealand biosimilars market size, by oncology, 2017-2021 (USD Million)

TABLE 1154.    New Zealand biosimilars market size, by oncology, 2022-2030 (USD Million)

TABLE 1155.    New Zealand biosimilars market size, by leukemia, 2017-2021 (USD Million)

TABLE 1156.    New Zealand biosimilars market size, by leukemia, 2022-2030 (USD Million)

TABLE 1157.    New Zealand biosimilars market size, by manufacturer, 2017-2021 (USD Million)

TABLE 1158.    New Zealand biosimilars market size, by manufacturer, 2022-2030 (USD Million)

TABLE 1159.    New Zealand biosimilars market size, by technology, 2017-2021 (USD Million)

TABLE 1160.    New Zealand biosimilars market size, by technology, 2022-2030 (USD Million)

TABLE 1161.    Singapore biosimilars market size, by product, 2017-2021 (USD Million)

TABLE 1162.    Singapore biosimilars market size, by product, 2022-2030 (USD Million)

TABLE 1163.    Singapore biosimilars market size, by recombinant non-glycosylated proteins, 2017-2021 (USD Million)

TABLE 1164.    Singapore biosimilars market size, by recombinant non-glycosylated proteins, 2022-2030 (USD Million)

TABLE 1165.    Singapore biosimilars market size, by recombinant glycosylated proteins, 2017-2021 (USD Million)

TABLE 1166.    Singapore biosimilars market size, by recombinant glycosylated proteins, 2022-2030 (USD Million)

TABLE 1167.    Singapore biosimilars market size, by monoclonal antibodies, 2017-2021 (USD Million)

TABLE 1168.    Singapore biosimilars market size, by monoclonal antibodies, 2022-2030 (USD Million)

TABLE 1169.    Singapore biosimilars market size, by application, 2017-2021 (USD Million)

TABLE 1170.    Singapore biosimilars market size, by application, 2022-2030 (USD Million)

TABLE 1171.    Singapore biosimilars market size, by hematology, 2017-2021 (USD Million)

TABLE 1172.    Singapore biosimilars market size, by hematology, 2022-2030 (USD Million)

TABLE 1173.    Singapore biosimilars market size, by autoimmune disease, 2017-2021 (USD Million)

TABLE 1174.    Singapore biosimilars market size, by autoimmune disease, 2022-2030 (USD Million)

TABLE 1175.    Singapore biosimilars market size, by arthritis, 2017-2021 (USD Million)

TABLE 1176.    Singapore biosimilars market size, by arthritis, 2022-2030 (USD Million)

TABLE 1177.    Singapore biosimilars market size, by inflammatory bowel disease, 2017-2021 (USD Million)

TABLE 1178.    Singapore biosimilars market size, by inflammatory bowel disease, 2022-2030 (USD Million)

TABLE 1179.    Singapore biosimilars market size, by manufacturer, 2017-2021 (USD Million)

TABLE 1180.    Singapore biosimilars market size, by manufacturer, 2022-2030 (USD Million)

TABLE 1181.    Singapore biosimilars market size, by technology, 2017-2021 (USD Million)

TABLE 1182.    Singapore biosimilars market size, by technology, 2022-2030 (USD Million)

TABLE 1183.    Malaysia biosimilars market size, by product, 2017-2021 (USD Million)

TABLE 1184.    Malaysia biosimilars market size, by product, 2022-2030 (USD Million)

TABLE 1185.    Malaysia biosimilars market size, by recombinant non-glycosylated proteins, 2017-2021 (USD Million)

TABLE 1186.    Malaysia biosimilars market size, by recombinant non-glycosylated proteins, 2022-2030 (USD Million)

TABLE 1187.    Malaysia biosimilars market size, by recombinant glycosylated proteins, 2017-2021 (USD Million)

TABLE 1188.    Malaysia biosimilars market size, by recombinant glycosylated proteins, 2022-2030 (USD Million)

TABLE 1189.    Malaysia biosimilars market size, by erythropoietin, 2017-2021 (USD Million)

TABLE 1190.    Malaysia biosimilars market size, by erythropoietin, 2022-2030 (USD Million)

TABLE 1191.    Malaysia biosimilars market size, by application, 2017-2021 (USD Million)

TABLE 1192.    Malaysia biosimilars market size, by application, 2022-2030 (USD Million)

TABLE 1193.    Malaysia biosimilars market size, by hematology, 2017-2021 (USD Million)

TABLE 1194.    Malaysia biosimilars market size, by hematology, 2022-2030 (USD Million)

TABLE 1195.    Malaysia biosimilars market size, by oncology, 2017-2021 (USD Million)

TABLE 1196.    Malaysia biosimilars market size, by oncology, 2022-2030 (USD Million)

TABLE 1197.    Malaysia biosimilars market size, by leukemia, 2017-2021 (USD Million)

TABLE 1198.    Malaysia biosimilars market size, by leukemia, 2022-2030 (USD Million)

TABLE 1199.    Malaysia biosimilars market size, by manufacturer, 2017-2021 (USD Million)

TABLE 1200.    Malaysia biosimilars market size, by manufacturer, 2022-2030 (USD Million)

TABLE 1201.    Malaysia biosimilars market size, by technology, 2017-2021 (USD Million)

TABLE 1202.    Malaysia biosimilars market size, by technology, 2022-2030 (USD Million)

   

Charts & Figures

FIG. 1    Top-down approach

FIG. 2    Bottom-up approach

FIG. 3    Data validation

FIG. 4    Biosimilars industry 360⁰ synopsis, 2017-2030

FIG. 5    Industry segmentation

FIG. 6    Global biosimilars market size, 2017 – 2030 (USD Million)

FIG. 7    Growth potential analysis, by product

FIG. 8    Growth potential analysis, by application

FIG. 9    Growth potential analysis, by manufacturer

FIG. 10    Growth potential analysis, by technology

FIG. 11    Porter’s analysis

FIG. 12    Competitive matrix analysis, 2021

FIG. 13    PESTEL analysis

FIG. 14    Key segment trends, by product

FIG. 15    Key segment trends, by application

FIG. 16    Key segment trends, by manufacturer

FIG. 17    Key segment trends, by technology

FIG. 18    Key regional trends

FIG. 19    Competitive dashboard, 2021